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Gammaretrovirus-like sequences occur in most vertebrate genomes. Murine Leukemia Virus (MLV) like retroviruses (MLLVs) are
a subset, which may be pathogenic and spread cross-species. Retroviruses highly similar to MLLVs (xenotropic murine retrovirus
related virus (XMRV) and Human Mouse retrovirus-like RetroViruses (HMRVs)) reported from patients suﬀering from prostate
cancer (PC) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) raise the possibility that also humans have been
infected. Structurally intact, potentially infectious MLLVs occur in the genomes of some mammals, especially mouse. Mouse
MLLVs contain three major groups. One, MERV G3, contained MLVs and XMRV/HMRV. Its presence in mouse DNA, and the
abundance of xenotropic MLVs in biologicals, is a source of false positivity. Theoretically, XMRV/HMRV could be one of several
MLLV transspecies infections. MLLV pathobiology and diversity indicate optimal strategies for investigating XMRV/HMRV in
humans and raise ethical concerns. The alternatives that XMRV/HMRV may give a hard-to-detect “stealth” infection, or that
XMRV/HMRV never reached humans, have to be considered.
1.Introduction
Recent reports of human gammaretroviruses highly similar
to murine gammaretroviruses in PC and ME/CFS patients
raisequestionsregarding(i)theoccurrenceofsuchretroviral
sequences in murine and other vertebrate genomes, (ii)
probable routes of spread of such viruses, and (iii) available
methods for the detection of infection with them. In this
review, we apply a phylogenetic aspect to the occurrence
of XMRV/HMRV in genomes, and to the diagnostic search
for it in humans. The comparative approach [1] can also
enhance the study of pathobiology and epidemiology of
XMRV/HMRV. Given the recent great activity in the ﬁeld,
the review cannot be exhaustive. Indeed, reports indicating
that all XMRV/HMRV ﬁndings in humans may be due to
diﬀerent forms of laboratory contamination [2, 3] stress the
need for a critical evaluation.
2. The GenusGammaretrovirus
2.1. General. Murine leukemia viruses (MLVs) are gam-
maretroviruses which may be both exogenous (trans-
mits between individuals, i.e., horizontally) or endogenous
(proviruses integrated into the germ line of mice and2 Advances in Virology
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Figure 1: Simpliﬁed phylogeny of gammaretroviruses based on over 2000 gammaretrovirus-like sequences with one zinc ﬁnger in Gag,
from selected vertebrate genomes (in a ﬁrst version of RetroBank) and reference gammaretroviruses. Retroviral groups which occur in
phylogeneticallydistantvertebratehosts,indicatingcross-speciestransmissionevents,areshowninred.Theneighbor-joiningtreewasbased
on an alignment of 105 reference and consensus Pol amino acid sequences. Only the major branches are shown. As explained in the text,
they were provisionally named after the cosegregating HERV group. The group of “MLV-like viruses,” MLLVs, at least 60% similar in Pol, is
boxed in. The similarity is calculated from the inverted ratio of the BLASTP score of the sequence against itself to another sequence, or to a
consensusPolsequence.Sometwo-zincﬁngersequences(ERV-HF,containingHERV-HandHERV-F)wereincludedasareference.Although
the clustering included several genomes, the groups were named from the human sequence representative. MuERV: mouse endogenous
retrovirus. MmERV is from Bromham et al. [13], and MdERV is Mus dunni ERV from Wolgamot et al. [14]. GLN MuERV is from Ribet
et al.[15].Symbols: ∗position of XMRV/HMRV, §recombinant MuERVSp496-5Sb [16]f r o mMus spretus, hortulanus endogenous murine
virus, HEMV, from Mus spicilegus [17], # MuRRS [18], and MuERVC [19]. An ERV-S sequence [20] was used to root the tree. It came from
HERV-S, a sequence intermediate to spuma-, epsilon-, and gammaretroviruses. It belongs to the so-called “ERV3 family” according to the
RepBase nomenclature [21]. This large clade is also called “Class III ERVs.” It should not be confused with the ERV3 group shown in the
ﬁgure. The hand symbols denote proviruses with one and two zinc ﬁngers in Gag, respectively. The murine gammaretroviral groups G1-G3
are described in greater detail in a forthcoming paper (Elfaitouri et al., accepted, Plos One).
thereby being transmitted to the next generation, i.e.,
vertically).Gammaretrovirusesweredeﬁnedfromexogenous
retroviruses with MLV as a reference. The vast amount
of genomic information now available shows that they
are included in the large Class I ERV clade. Figure 1
depicts the major gammaretroviral groups, based on a
clustering analysis of polymerase sequences of a large
number of endogenous sequences. Using MLVs (Genbank
ID J02255, Locus MLMCG) as a taxonomical starting point,
gammaretroviruses related to MLVs can be labeled “MLV-
like retroviruses” and are here referred to as “MLLVs.”
Endogenous versions of MLLVs occur in the genomes
of some mammals and marsupials. The major branches
segregated with previously characterized HERV groups,
named after primer binding site, PBS, usage. This usage was
found to be retained in the larger context (data not shown).
These branches were therefore provisionally named after the
respective HERV group. MLLVs are boxed in. They wereAdvances in Virology 3
deﬁned as a cluster of polymerase (Pol) sequences which
were at least 60% similar, including the MLVs. The similarity
was based on the BLASTP score of their Pol amino acid
sequences to each other. The concept “MLLV” is justiﬁed for
thepurposeofthisreviewtoencompasssimilarprovirusesof
phylogenetically distant vertebrates. Their wide distribution,
in pigs, primates, rodents, and koalas, demonstrates a
tendency to interspecies spread, potentially relevant both for
human disease [4–9] and xenotransplantation [10–12].
The human genome also contains remnants of infec-
tions with retroviruses highly related to MLLVs, HERV-T.
However, these were integrated in the rather distant past.
In contrast, MLLVs have repeatedly infected nonmurine
vertebrates in the not so distant past, judging from the low
degree of divergence of entire proviral and LTR sequences.
Mediterranean and middle Eastern cats [22], turkeys [23],
gibbonapes[24,25],andkoalas[26,27]havebeen“invaded”
by MLLVs. This is further discussed below. In some hosts,
they are both endogenous and exogenous, in others just
exogenous. In the infected animals, exogenous MLLVs are
associated with signiﬁcant disease like encephalitis, malig-
nancy(leukemiaandlymphoma),wasting,immunosuppres-
sion, and autoimmunity. This makes it especially important
to establish if also the human species is now “invaded” by a
murine MLLV, that is, XMRV/HMRV.
2.2. Properties
2.2.1. The Gammaretrovirus Genome. Gammaretroviruses
have a simple genome (Figure 2), that is, there are no known
additional overlapping reading frames for nonstructural
regulatory proteins such as those which occur in betaretro-
viruses, deltaretroviruses, and lentiviruses. Moloney MLV is
the reference gammaretrovirus [28]. Despite being simple,
MLVs have some distinguishing features. The gag gene
may have alternative translational start sites, giving rise to
both a myristoylated Gag polyprotein, which contains the
inner structural proteins, and a glycosylated Gag membrane
protein. Many of them have a phosphoprotein following the
matrix protein p15, called p12. The major Gag protein is
p30, the capsid protein. It is responsible for many of the
antigenic cross-reactions which gave rise to the acronym
Gag (“group-speciﬁc antigen”). Further, like many other
gammaretroviruses, the MLLVs have one zinc ﬁnger in the
NucleoCapsid, NC, portion of Gag (the p10 protein), instead
of the customary two [29]. The ﬁrst ﬁnger is replaced with
a highly charged sequence, binding to retroviral genomic
RNA in a somewhat diﬀerent way compared to two zinc
ﬁnger retroviruses. The zinc ﬁnger status is here used as a
taxonomic marker of a subset of gammaretroviruses [30].
All MLLVs have one zinc ﬁnger. Occasional readthrough of
a Gag stop codon creates Gag-Pol polyproteins.
Another structural genomic aspect is that retroviruses
with simple genomes like alpharetroviruses and gam-
maretroviruses occasionally may take up an oncogene in
their genome, to form acutely transforming (“sarcoma”)
viruses [28]. They are often replication deﬁcient. They
then need a replication competent virus, a helper virus,
to replicate. The so-called murine AIDS (MAIDS) virus
variants are also defective, producing a new Gag protein
(p60) which contains part of the p12 protein and a T
cell neoepitope [31–33]. Likewise, the feline leukemiavirus
immunodeﬁciency-inducing defective virus (FeLV-T) has a
mutated Env [34]. Immunodeﬁciency associated with this
variant is sometimes called “Feline AIDS,” FAIDS, although
the feline immunodeﬁciency virus can cause another form
of (FAIDS). Recombination between exo- and endogenous
M L L Vs e q u e n c e si sc o m m o ni nb o t hm i c ea n dc a t s[ 35].
MLVs can cause cancer in at least two ways, either
through incorporation of an oncogene, or by integration
near 5 ends of transcription units and associated CpG-rich
portions [28]. The propensity to integrate into or next to
p r o m o t e r si sag a m m a r e t r o v i r a ls p e c i a l t y[ 36–38]. Random
integration next to an oncogene is a frequent cause of
leukemia inMLV-infectedanimals. Humansarenotimmune
to this mechanism. MLV-basedgenetherapeuticvectorshave
the same target speciﬁcity [37, 39], see also [40]. Thus,
an MLLV infecting humans would be expected to cause
leukemias or lymphomas.
Finally,theenvelopeproteins(SurfaceUnit;SU,gp70and
TransMembrane protein; TM, p15E) are central for tissue
tropism, immunogenicity, and for immunosuppression. The
latter contains the conserved so-called “immunosuppressive
domain” (ISD) [41–45] whose mode of action is still
poorly known. Thus, despite their basic structural simplicity,
MLLVs can display a complex pathobiology.
2.2.2. Occurrence among Vertebrates. Ar i c hs o u r c eo fv e r t e -
brate information is the collection of ERV sequences in an
early version of RetroBank [47]. The program RetroTector
(ReTe) [48] was used to collect more than 40.000 proviruses
from whole genome analyses of thirty vertebrate genomes.
ReTe is based on a pattern recognition algorithm. It uses the
order of and distances between conserved retroviral motifs
to detect and characterize retroviral sequences from large
genomic data sets. A score is calculated from the degree
of ﬁt to a collection of conserved motifs from all seven
retroviral genera. The higher the score, the better the ﬁt to
a structural model which encompasses most orthoretroviral
and also some retrovirus-like sequences. A provisional genus
is designated by counting the best-ﬁtting motifs from each
genus.
Gammaretrovirus-like sequences were detected in all of
the 30 genomes (those reported in [48] plus the turkey
genome).Thosescoringabove1000byRetroTector,andwith
only one zinc ﬁnger (n = 2534, from marmoset 32, dog 41,
guinea pig 211, horse 4, duckbill 16, lemur 43, orangutan
82, rhesus 204, pig 79, tree shrew 11, lizard 162, cow 37,
human 143, opossum 393, mouse 515, chimpanzee 192,
rat 361, and zebra ﬁnch 8), were selected from RetroBank.
The mouse genome assembly employed was mm8, from
a C57 black mouse. Some were from the MLLV subset,
as deﬁned in Figure 1. A study of their taxonomy was
initiated by clustering and consensus sequence calculation
at the 85% similarity level. It resulted in 75 interhost Pol
consensus sequences which together with reference Pols were
used to build the tree shown in the simpliﬁed form in
Figure 1. This is part of JBs ongoing work with retroviral4 Advances in Virology
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Figure 2: Structure and genome of a gammaretrovirus. The nucleocapsid is built from a hexameric lattice [46]. MA: matrix (p15), CA:
capsid (p30), NC: nucleocapsid (p10), PR: protease, RT: reverse transcriptase (shown as a green dot), RH: RNAse H, IN: integrase, SU:
surface unit (gp70), and TM: transmembrane protein (p15E). P12 is a small protein encoded from the portion between p15 and p30 in
gag. LTR: long terminal repeat. The translation of glycoGag and normal Gag is indicated by the respective ribosome symbols. A Gag-Pol
polyprotein is occasionally produced by suppression of a stop codon at the end of gag.
taxonomy and will be reported in a more complete form in
future papers. Especially many seemingly intact, potentially
infectious MLLV proviruses were found in the mouse. In this
review, we will concentrate on MLLV of mice and mention
other rodents, pigs, felines, primates, and some marsupials.
Of 7646 retroviral sequences detected in the mm8 assembly,
1461 were gammaretrovirus-like [47]. Some of the latter
(300 proviruses) scored higher than 2000 by ReTe (Figures
3 and 4). This is a high score, achieved only by complete or
virtually complete proviruses. Indeed, they all turned out to
be complete proviruses with very few stop or shift (indel)
mutations which could incapacitate the virus. As mentioned
above, the 300 proviruses included 35 which had no such
mutations. They were structurally “intact” by bioinformatic
criteria. The 35 had less than 0.5% LTR divergence. They
are marked with green arrows in the Pol tree presented in
Figure 3. Thus, the 35 proviruses have hallmarks of being
infectious and also belong to the most recently integrated
murine ERVs.
Three major groups of high scoring murine gammar-
etroviral proviruses, named gamma 1–3 (G1–G3), were
observed.
Group G1 (188 members, 10 with open reading frame
(ORF) in gag, pro, pol, and env) members encompassed the
“Mus musculus endogenous retrovirus” (MmERV; GenBank
Id AC005743 [13], as interpreted by RetroTector online
[49]). Mus dunni ERV (AF053745) [14] is highly related. The
most similar nonmouse viruses were from rat chromosomes
7 and 17 (nr4 assembly), and more distantly, gibbon
ape leukemia virus (GaLV, PCGGPE) and koala retrovirus
(KoRV, AF151794) sequences.
Group G2 (59 members, 3 with ORF in gag, pro, pol, and
env) contained the GLN retroviruses described by Ribet et al.
[15]. It was most related to rat sequences at chromosomes 7
and 9.
A group of porcine ERVs (PERVs) located at chromo-
somes 9, 10, 12, and 4 (susScr10 assembly) were 74% similar
to the consensus of Group G2, and 70% to the consensus of
Group G1. MuRRS [18]a n dM u E R V C[ 19]s e q u e n c e sw e r e
ancestral to groups G1 and G2 at the level of 64% similarity
to their consensuses.
Group G3 (53 members, 22 with ORF in gag, pro,
pol, and env) encompassed the ampho-, eco-, xeno-, poly-,
and modiﬁed polytropic MLVs [50]. Most of the MLVs
which have been prominent in retrovirological research for
half a century are ecotropic [51]. Amphotropic MLVs are
primarily exogenous, while the others are mainly endoge-
nous. The recombinant endogenous Mus spretus proviruses
[16] emerged between modiﬁed polytropic and xenotropic
proviruses. The HEMV provirus was at the root of the G3
branch [17].
The three major groups were discernible in trees
made with several techniques resulting from alignment of
nucleotides and protein sequences of the three genes gag,
pol, and env. They represent three evolutionarily recent
bursts of gammaretroviral proliferation in the mouse and its
immediate progenitors. The third group, which includes the
retroviruses reported in the human diseases, prostate cancerAdvances in Virology 5
musmus Chr12 23639259 2450 po  C Pz0/ 0
musmus Chr12 24232686 2523 po  C Pz0/ 0
musmus Chr4 123354415 2334 po  C Pz0/ 2
musmus Chr12 20963947 2266 po  C Pz4/ 0
musmus Chr5 9854828 2350 po  C Pz2/ 0
musmus Chr14 52643653 2319 po  C Pz0/ 0
musmus Chr3 96458134 2321 po  C Pz1/ 0
musmus Chr2 25549391 2052 po  C Pz4/ 2
musmus Chr4 31 158729 2335 po  C Pz1/ 0
musmus Chr3 10857898 2158 po  C Pz1/ 1
musmus Chr7 62535812 2471 po  C Pz2/ 0
musmus Chr4 143285616 2223 po  C Pz2/ 0
musmus Chr4 90367080 2459 po  C Pz2/ 0
musmus Chr7 85330013 2396 po  C Pz1/ 0
musmus Chr9 19707318 2295 po  C Pz2/ 0
musmus Chr16 3107315 2157 po  C Pz0/ 1
musmus Chr16 3275036 2215 po  C Pz0/ 1
musmus Chr7 16826508 2416 po  C Pz1/ 0
musmus Chr9 6804768 2496 po  C Pz0/ 0
musmus Chr9 6804768 2483 po  C Pz0/ 0
musmus Chr7 13722716 2371 po  C Pz2/ 0
musmus Chr16 61201576 2398 po  C Pz0/ 1
musmus Chr2 138262497 2403 po  C Pz1/ 0
musmus Chr13 78107530 2275 po  C Pz0/ 0
musmus Chr10 47444316 2180 po  C Mz1/ 0
musmus Chr19 13109265 2405 po  C Pz2/ 1
musmus Chr3 2366 po  C Pz0/ 0 3249466
musmus ChrYR 13247086 2327 po  C Pz3/ 0
musmus ChrYR 3831942 2328 po  C Pz3/ 0
musmus Chr13 35021 135 2294 po  C Pz1/ 2
musmus Chr1 1 12 1136108 2337 po  C Pz0/ 0
musmus Chr1  119978260 2348 po  C Pz0/ 1
musmus Chr18 6355349 2256 po  C Pz1/ 1
musmus Chr5 9561 1246 2244 po  C Pz1/ 1
musmus Chr5R 1005041 2166 po  C Pz0/ 0
musmus Chr5 94686917 2338 po  C Pz2/ 0
musmus Chr12 19930599 2025 po  C Pz1/ 3
musmus Chr12 44540601 2271 po  C Pz0/ 1
musmus Chr12 77663152 2400 po  C Pz2/ 0
musmus ChrX 2422 po  C Pz0/ 0 122485908
musmus ChrX 25720491 2091 po  C Pz1/ 3
musmus Chr12 52231624 2467 po  C Pz1/ 0
musmus Chr3  111 23338 2314 po  C Pz1/ 0
musmus Chr19 9616180 2432 po  C Pz0/ 1
musmus Chr6 59821337 2342 po  C Pz0/ 1
musmus Chr10 78270986 2308 po  C Pz0/ 1
musmus Chr1 1 47262836 2429 po  C Pz1/ 1
musmus Chr19 40015556 2356 po  C Pz2/ 1
musmus Chr7 42296817 2197 po  C Pz0/ 1
musmus Chr2 41034625 2320 po  C Pz1/ 0
musmus Chr9 25914164 2354 po  C Pz2/ 1
musmus ChrX 2346 po  C Pz0/ 0 161151110
musmus ChrX 26583153 2502 po  C Pz1/ 1
musmus ChrX 27741 119 2510 po  C Pz1/ 1
musmus ChrX 28668814 2535 po  C Pz1/ 1
musmus ChrX 26939449 2499 po  C Pz1/ 1
musmus ChrX 28089696 2529 po  C Pz1/ 1
musmus ChrX 29493445 2458 po  C Pz1/ 1
musmus ChrX 31327254 2438 po  C Pz1/ 1
musmus Chr10 55324861 2409 po  C Pz2/ 0
musmus ChrX 51971219 2230 po  C Pz2/ 1
musmus Chr13 68562177 2285 po  C Pz1/ 1
musmus Chr13 688251 10 2358 po  C Pz2/ 0
musmus Chr13 1 12849620 2465 po  C Pz0/ 0
MmERV Pol AC005743
musmus Chr8 2348 po  C Pz0/ 0 76141904
musmus Chr1 1001 17419 2325 po  C Pz2/ 0
musmus ChrYR 14435559 2156 po  C Pz1/ 0
musmus Chr13 86668875 2163 po  C Pz2/ 0
musmus Chr8 4959420 2074 po  C Pz1/ 1
musmus Chr2 67930798 2267 po  C Pz3/ 1
musmus Chr1 142780526 2475 po  C Pz2/ 0
musmus Chr2 55605859 2430 po  C Pz1/ 1
musmus Chr14 8217491 2380 po  C Pz2/ 0
musmus Chr9 6703246 2361 po  C Pz2/ 1
musmus Chr9 7407606 2253 po  C Pz0/ 1
musmus Chr9 7407328 2543 po  C Pz0/ 1
musmus Chr3 67513064 2300 po  C Pz0/ 0
musmus ChrX 36617602 2245 po  C Pz1/ 1
musmus Chr6 13410749 2225 po  C Pz0/ 1
musmus Chr1 27674279 2288 po  C Pz2/ 1
musmus Chr15 15004671 2321 po  C Pz2/ 1
musmus Chr17 18094247 2169 po  C Pz0/ 0
musmus Chr17 20451942 2302 po  C Pz2/ 0
musmus Chr10 42662 11 2384 po  C Pz1/ 0
musmus Chr3 16432285 2375 po  C Pz0/ 0
musmus Chr13 50732587 2452 po  C Pz2/ 1
musmus Chr13 68413662 2416 po  C Pz3/ 0
musmus Chr7 20210541 2155 po  C Pz1/ 0
musmus Chr7 20210495 2128 po  C Pz1/ 0
musmus Chr7 22620924 2003 po  C Pz2/ 0
musmus Chr17 58525679 2277 po  C Pz4/ 0
musmus Chr9 3947717 2431 po  C Pz1/ 0
musmus Chr7 31649885 2253 po  C Pz0/ 1
musmus Chr7 32382271 2428 po  C Pz0/ 1
musmus Chr7 32609167 2405 po  C Pz0/ 1
musmus Chr6 10870226 2075 po  C Pz2/ 1
musmus ChrX 452161 13 2421 po  C Pz2/ 1
musmus Chr19 29751613 2455 po  C Pz1/ 1
musmus Chr18 74384552 2441 po  C Pz0/ 2
musmus Chr4 143392767 2195 po  C Pz2/ 2
musmus Chr1 1 75181662 2279 po  C Pz1/ 3
musmus Chr15 49007539 2505 po  C Pz0/ 1
musmus Chr1 85024403 2443 po  C Pz0/ 0
musmus Chr1 87307992 2471 po  C Pz0/ 0
musmus Chr2 68347295 2541 po  C Pz0/ 1
musmus Chr9 4855377 2480 po  C Pz0/ 0
musmus Chr15 32809701 2510 po  C Pz1/ 2
musmus Chr5 6489438 2503 po  C Pz1/ 1
musmus Chr13 3180552 2400 po  C Pz0/ 0
musmus Chr18 86334894 2275 po  C Pz0/ 1
musmus Chr5 144029052 2498 po  C Pz1/ 0
musmus ChrX 4473889 2519 po  C Pz1/ 0
musmus ChrX 3107370 2210 po  C Pz1/ 0
musmus ChrX 3107092 2505 po  C Pz1/ 0
musmus Chr14 39042987 2287 po  C Pz1/ 1
musmus Chr18 42601670 2372 po  C Pz2/ 0
musmus Chr4 142945865 2399 po  C Pz0/ 1
musmus Chr7 42172126 2451 po  C Pz3/ 0
musmus ChrX 22753149 2567 po  C Pz0/ 1
musmus ChrX 73147008 2584 po  C Pz2/ 1
musmus Chr7 10085860 2245 po  C Pz0/ 1
musmus Chr7 103168275 2419 po  C Pz1/ 0
musmus Chr6 129778341 2480 po  C Pz1/ 0
musmus Chr6 9246408 2574 po  C Pz3/ 0
musmus Chr8 75759184 2254 po  C Pz0/ 1
musmus Chr6 104192593 2431 po  C Pz1/ 1
musmus Chr1 1 10344713 2403 po  C Pz0/ 0
musmus Chr16 19516342 2262 po  C Pz2/ 0
musmus ChrX  110244634 2372 po  C Pz3/ 1
musmus ChrX 3017764 2183 po  C Pz2/ 1
musmus Chr6 19594284 2520 po  C Pz2/ 0
musmus Chr5 766639 11 2130 po  C Pz1/ 1
musmus Chr5R 2917745 2096 po  C Pz1/ 2
musmus Chr5R 363468 2109 po  C Pz1/ 1
musmus Chr5R 2051415 2056 po  C Pz1/ 1
musmus Chr5 76673772 2226 po  C Pz1/ 1
musmus Chr5R 2907883 2222 po  C Pz1/ 1
musmus Chr5R 2061443 2098 po  C Pz2/ 1
musmus Chr5R 353440 2084 po  C Pz2/ 1
musmus Chr5 95293762 2134 po  C Pz2/ 0
musmus Chr5R 23133 2172 po  C Pz2/ 1
musmus Chr5R 698499 2160 po  C Pz2/ 1
musmus Chr4 40848866 2446 po  C Pz0/ 1
musmus Chr7 19466915 2431 po  C Pz1/ 1
musmus Chr7 22012805 2444 po  C Pz1/ 1
musmus Chr7 2420 po  C Pz0/ 0 2042198 4
musmus Chr6 10346803 2533 po  C Pz1/ 0
musmus Chr8  116462276 2500 po  C Pz1/ 1
musmus Chr2 84699377 2410 po  C Pz0/ 1
musmus Chr5 58614499 251 1 po  C Pz1/ 0
musmus ChrX 75140573 2573 po  C Pz2/ 0
musmus Chr10 3947641 2476 po  C Pz0/ 1
musmus ChrX  117175129 2177 po  C Xz0/ 0
musmus Chr13 68917752 2618 po  C Pz0/ 0
musmus Chr4 2530 po  C Pz0/ 0 143351516
musmus Chr2 2572 po  C Pz0/ 0 181848717
musmus ChrX 2551 po  C Pz0/ 0 69002389
musmus Chr19 13997386 2025 po  C Pz3/ 6
musmus Chr12 23063728 2552 po  C Pz0/ 0
musmus Chr8 20181859 2440 po  C Pz6/ 1
musmus Chr9 17870138 2390 po  C Pz1/ 0
musmus Chr5 94676896 2218 po  C Pz0/ 1
musmus Chr12 7167658 2286 po  C Pz1/ 1
musmus Chr7 27736610 2361 po  C Pz1/ 2
musmus Chr12 2492 po  C Pz0/ 0 69841080
musmus Chr9 90737869 2531 po  C Pz2/ 0
musmus Chr1 147966500 2505 po  C Pz0/ 0
musmus Chr4 39044302 2576 po  C Pz2/ 0
musmus Chr1 2547 po  C Pz0/ 0 197059344
musmus Chr14 37020689 2481 po  C Pz1/ 0
musmus Chr13 20666097 2518 po  C Pz0/ 1
musmus Chr17 32782428 2363 po  C Pz1/ 5
musmus Chr5 10627682 2477 po  C Pz1/ 1
musmus ChrX  116205149 2363 po  C Pz1/ 1
musmus Chr12 24421810 2476 po  C Pz1/ 0
musmus Chr7 106162675 2568 po  C Pz1/ 1
musmus Chr3 27214964 2480 po  C Pz1/ 0
musmus Chr8 28769833 2443 po  C Pz0/ 0
musmus Chr7 56788381 2389 po  C Pz1/ 1
musmus ChrX 85272635 2458 po  C Pz1/ 1
musmus Chr6 9818958 2151 po  C Pz1/ 1
MDERV Po l AF053745
musmus Chr12 88605018 2422 po  C Pz1/ 1
musmus Chr7 23024544 2465 po  C Pz1/ 0
musmus Chr9 12101539 2049 po  C Pz6/ 2
rn4 Pol CHR17 5186121 c 93
rn4 Pol CHR7 31839324 c 92
musmus Chr7 33735121 2134 po  C Pz2/ 4
musmus Chr1 1 9790554 2051 po  C Pz6/ 6
musmus Chr2 27317207 2123 po  C Pz1/ 4
musmus Chr5 105161 106 2105 po  C Pz4/ 2
GALV Pol
KoRV Pol AF151794
musmus Chr1 104629573 2102 po  C Pz9/ 8
musmus Chr1 102614371 2178 po  C Pz4/ 4
musmus Chr14 41247460 2194 po  C Pz2/ 0
musmus Chr4 145841008 21 16 po  C Pz1/ 1
musmus Chr14 40907571 2192 po  C Pz1/ 0
musmus Chr17 94976514 2323 po  C Pz0/ 1
musmus Chr4 145569452 2153 po  C Pz2/ 2
musmus Chr4 14651 1565 2092 po  C Pz2/ 1
rn4 Pol CHRUn 3262691 c 90
rn4 Pol CHR7 74285691 c 91
rn4 Pol CHR9 2586497 c 91
susScr10 Pol CHR4 47233287 c 90
susScr10 Pol CHR9 151461 131 c 90
susScr10 Pol CHR12 29233668 c 90
susScr10 Pol CHR15 71670155 c 90
musmus Chr12 20481297 2293 po  C Pz0/ 0
musmus ChrX 1 10081585 2496 po  C Pz1/ 1
musmus Chr12 21890390 2002 po  C Pz7/ 3
musmus Chr18 18992414 2020 po  C Pz7/ 2
musmus Chr3 94762160 2196 po  C Pz1/ 5
musmus Chr4 1 1111258 2316 po  C Pz5/ 1
musmus Chr4 1 1111258 2322 po  C Pz5/ 1
musmus Chr5 82708425 2436 po  C Pz0/ 1
musmus Chr5 82708425 2429 po  C Pz0/ 1
musmus Chr6 58755056 2495 po  C Pz1/ 0
musmus Chr8 26596457 2023 po  C Xz2/ 2
musmus Chr17 3436831 1 2296 po   C Tz2/0
musmus Chr4 3291272 2240 po  C Pz10/2
musmus Chr7 12068859 2095 po   C Tz4/1
musmus ChrX 156453233 2050 po   C Tz7/4
musmus Chr2 203071 10 2516 po   C Tz0/0
musmus Chr1 58585489 2220 po   C Tz2/0
musmus Chr13  118292973 2010 po  C Pz4/ 0
musmus Chr8 124718935 2282 po   C Tz0/0
musmus ChrY 2041229 2026 po   C Tz4/4
musmus Chr4 94746451 2317 po   C Tz2/0
musmus Chr13 68140880 2546 po  C Xz2/ 0
musmus Chr6 132935927 2459 po  C Pz0/ 0
musmus Chr4 74538467 2372 po   C Tz1/2
musmus Chr14 52521890 2403 po   C Tz0/0
musmu 2516 po   C Tz0/0 s Chr1 83868369
musmus Chr10 26624616 2529 po   C Tz0/0
musmus Chr10 17014683 2500 po  C Pz0/ 0
musmus Chr4 51892727 2510 po   C Tz0/0
musmus Chr15 83021703 2458 po   C Tz0/1
musmus Chr4 53968674 2427 po   C Tz1/0
musmus Chr12 44831985 2401 po   C Tz2/0
musmus Chr16 55879954 2312 po   C Tz2/0
musmus Chr4 39571 122 2433 po   C Tz2/1
musmus 2495 po   C Tz0/0 Chr1 0 25585205
musmus Chr2 94602089 2541 po  C Xz1/ 0
musmus Chr6 7669279 2514 po   C Tz0/0
musmus 2470 po  C Pz0/ 0 Chr11 9350834
musmus Chr10 86106187 2487 po   C Tz1/0
musmus Chr18 24683321 2500 po  C Pz1/ 0
musmus Chr7 5220201 1 2486 po   C Tz0/0
musmus Chr9 25612912 2455 po   C Tz1/0
musmus Chr9 25612912 2463 po   C Tz1/0
musmus Chr15 19950298 2420 po   C Tz2/0
musmus Chr12 41784059 2347 po   C Tz1/0
musmus Chr1 52257434 2403 po   C Tz2/2
musmus Chr3 16984867 2328 po   C Tz1/1
musmus Chr14  112984891 2339 po   C Tz0/1
musmus ChrX 72524699 2024 po  C Xz1/ 1
musmus Chr13 104833012 2476 po  C Pz1/ 1
musmus Chr3 55674149 2471 po   C Tz1/0
musmus Chr4 34538284 2471 po   C Tz1/0
musmus ChrX 41488765 2070 po   C Tz4/3
musmus ChrY 1872546 2035 po   C Tz2/0
cavPor Pol CHRP24 15683290 c 88
cavPor Pol CHRP13 44305741 c 88
cavPor Pol CHRP2 141 119329 c 87
cavPor Pol CHRP23 99496779 c 87
cavPor Pol CHRP17 18032986 c 88
cavPor Pol CHRP7 90672638 c 87
CAVPOR1 ChrP1 83278939 2150 po  C Fz0/ 0
cavPor Pol CHRP20 52335285 c 88
cavPor Pol CHRP2 59706460 c 88
cavPor Pol CHRP10 20257983 c 88
cavPor Pol CHRP24 7271069 c 87
cavPor Pol CHRP10 15288221 c 87
cavPor Pol CHRP23 98272562 c 87
cavPor Pol CHRP8 104691003 c 87
cavPor Pol CHRP13 10270031 c 87
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felCat Pol CHRP16  11126973 c 90
felCat Pol CHRP31 88413417 c 90
felCat Pol CHRP10 98134121 c 91
felCat Pol CHRP13 46599734 c 90
felCat Pol CHRP12 26632935 c 91
felCat Pol CHRP4 43417679 c 89
rheMac2 Pol CHRA 91524508 c 91
rheMac2 Pol CHRB 289433678 c 90
panTro2 Pol CHR1 24165782 c 90
panTro2 Pol CHR Y 21678398 c 90
panTro2 Pol CHR Y 21910354 c 91
oryCun Pol CHRP2 54410478 c 89
felCat Pol CHRP3 57331964 c 99
felCat Pol CHRP27 6771612 c 98
Fe LV Pol M18247
rn4 Pol CHR3 126586378 c 93
rn4 Pol CHRUn 56537573 c 93
rn4 Pol CHRUR 225006 c 93
rn4 Pol CHRX 159655885 c 93
rn4 Pol CHR2 128855619 c 93
rn4 Pol CHR6 171 12204 c 91
rn4 Pol CHR7 700 11574 c 92
rn4 Pol CHR7 42837719 c 92
rn4 Pol CHRUn 21 132698 c 91
rn4 Pol CHRX 1 14586881 c 91
rn4 Pol CHR18 16239921 c 93
rn4 Pol CHR15 55093962 c 93
rn4 Pol CHR5 51528025 c 87
rn4 Pol CHR14 70068348 c 93
rn4 Pol CHR5 162275009 c 93
rn4 Pol CHR14 45822024 c 90
rn4 Pol CHR6 84256315 c 92
rn4 Pol CHR14 45623205 c 93
rn4 Pol CHR3 836581 16 c 93
rn4 Pol CHR1 1 44625290 c 93
rn4 Pol CHR5 168554327 c 93
rn4 Pol CHR1 12807813 c 93
rn4 Pol CHR20 7659581 c 93
rn4 Pol CHR8 43587128 c 93
rn4 Pol CHR8 59636108 c 93
rn4 Pol CHR3 27618237 c 91
rn4 Pol CHR2 152589380 c 93
rn4 Pol CHR1 58019337 c 90
rn4 Pol CHR7 73716799 c 92
rn4 Pol CHR1 1 40258605 c 93
rn4 Pol CHR7 104840898 c 93
rn4 Pol CHRX 75105847 c 93
rn4 Pol CHR5 106444469 c 93
rn4 Pol CHR6 13981 199 c 92
rn4 Pol CHR4 17329961 c 93
rn4 Pol CHR7 15398560 c 93
rn4 Pol CHR15 92791054 c 93
rn4 Pol CHR1 6721 1080 c 94
rn4 Pol CHR2 188716457 c 93
rn4 Pol CHR3 23544488 c 94
rn4 Pol CHR2 14875612 c 94
rn4 Pol CHR8 16479431 c 94
rn4 Pol CHR18 44600261 c 80
rn4 Pol CHR13 56769191 c 93
rn4 Pol CHR2 122159081 c 93
rn4 Pol CHRX 108472082 c 93
rn4 Pol CHRUn 73590427 c 93
rn4 Pol CHR5 39576 c 92
rn4 Pol CHRX 63659664 c 93
mlmcg Po l
musmus Chr19 2906 po  C Pz0/ 0 60988354
musmus Chr8 88022347 2058 po   C Tz0/0
musmus Chr14 53484913 2707 po  C Pz0/ 0
musmus Chr4 3063 po   C Tz0/0 146062965
musmus Chr8 2936 po  C Pz0/ 0 44818939
musmus Chr9 2929 po   C Tz0/0 6223752 2
musmus Chr5 3147 po  C Pz0/ 0 23221035
XMRV VP62 Po l
musmus Chr1 173317855 2985 po  C Pz2/ 0
musmus Chr1 3099 po  C Pz0/ 0 172778230
musmus Chr9 41663510 2282 po  C Xz0/ 0
musmus Chr1 3 2914 po   C Tz0/0 68392368
musmus Chr4 2924 po  C Pz0/ 0 145371516
musmus Chr8 2984 po  C Pz0/ 0 126320498
musmus Chr12 55693276 2054 po  C Xz2/ 4
musmus Chr19 38440157 2106 po   C Tz2/0
musmus Chr3 67184346 2043 po   C Tz1/1
musmus Chr4 15169963 2038 po  C Pz2/ 0
musmus Chr5 24741 102 2861 po   C Tz1/0
musmus Chr8 126052021 2473 po  C Xz1/ 1
musmus Chr3 2906 po  C Pz0/ 0 152260864
musmus Chr1 1 102900091 2865 po  C Pz1/ 0
musmus Chr1 1 2944 po   C Tz0/0 8669884 9
musmus Chr1 1 60402203 2265 po   C Tz2/0
musmus Chr12 70465730 3000 po  C Xz0/ 0
musmus Chr1 1 2940 po  C Pz0/ 0 76365341
musmus Chr2 15946952 2937 po   C Tz0/0
musmus Chr1 0 2929 po   C Tz0/0 22424071
musmus Chr5 2960 po   C Tz0/0 4349652 7
musmus Chr5 122453776 2230 po  C Pz2/ 1
musmus Chr1 133470452 2862 po  C Pz0/ 0
musmus Chr10 4628507 2728 po   C Tz3/0
musmus Chr6 73223771 2547 po  C Xz1/ 1
musmus Chr5 1 10148316 2459 po   C Tz2/0
musmus Chr13 21819875 2591 po  C Pz0/ 0
musmus Chr7 2947 po   C Tz0/0 6400551 2
musmus Chr5 144923629 2818 po  C Pz0/ 0
musmus ChrX 3088 po   C Tz0/0 51501683
musmus ChrX 3057 po  C Sz0/ 0 51501683
musmus Chr4 2628 po  C Pz0/ 0 107652725
musmus Chr7 30400074 2187 po  C Xz1/ 0
musmus Chr1 1 2837 po  C Pz0/ 0 8820301
musmus Chr5 2945 po   C Tz0/0 78005469
musmus ChrX 14631230 2977 po   C Tz1/0
musmus Chr10 2937 po   C Tz0/0 41125197
musmus Chr10 8241473 2096 po   C Tz3/1
musmus Chr4 33126333 2394 po  C Pz3/ 0
musmus Chr13 100095189 2936 po   C Tz1/0
musmus Chr5 44422900 2950 po   C Tz0/0
musmus Chr16 93594754 2927 po   C Tz0/0
musmus Chr7 30397623 2584 po  C Pz1/ 0
musmus Chr2 2828 po  C Pz0/ 0 57038510
musmus Chr18 82828273 2874 po   C Tz0/0
musmus Chr1 184094018 2564 po   C Tz1/0
musmus Chr4 101369892 2594 po   C Tz1/0
musmus Chr7 2648 po  C Pz0/ 0 2932434 8
musmus Chr1 1 6658083 2387 po  C Pz1/ 1
musmus Chr1 193634451 2565 po   C Tz2/0
musmus Chr16 76026481 2929 po  C Pz1/ 0
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Figure 3: Neighbor-joining (NJ) tree based on Pol amino acid sequences of 300 high ReTe scoring MLLVs, the same as in Figure 4. The three
high-scoring murine gamma groups (G1–G3) segregate in a similar way as in a gag nt-based tree (Figure 4). Bootstrap values are shown to
the left of each branch. Structurally intact proviruses are marked with green arrows. GLN virus [15], MmERV, Mus dunni ERV (MdERV),
AKV MLV, and XMRV (VP62 clone) are marked with magenta arrows. Murine MLLVs occur from the black arrow in the tree and upwards.
The branch labels are either ERV host genus, chromosomal position, ReTe score, provisional genus, “po” for Pol, PBS, and number of stops
and frame shifts (“z 0/0” means 0 stops and 0 shifts in pol), or a reference Pol name. PBS assignments are made by the 1.01 version of
RetroTector. A more complete interpretation of PBS sequences of the G1-G3 groups is given in a forthcoming publication (Elfaitouri et al.,
accepted in Plos One). The major one zinc ﬁnger branch is indicated by the hand symbol. Nonmurine gammaretroviral ERV sequences were
taken from the prototype of RetroBank. Further information on which assemblies were used can be found in [47].6 Advances in Virology
and ME/CFS, contains the highest proportion of structurally
intact proviruses. It may thus have the greatest zoonotic
potential.
In fact, the ancestors of humans were not spared infec-
tionswithretrovirusesrelatedtoMLLV.Theso-calledHERV-
T is highly similar to MLLV (Figure 1). It has around 30
representatives in the human genome [52]. More distantly
related are ERV-E and ERV-9W. None of the three are struc-
turallyintactinthehumangenome(J.B.,unpublished).They
arediﬀerentenoughfromthemurineG3MLLVstonotinter-
fere with the nucleic acid based methods for XMRV/HMRV
detection (J.B., unpublished). Judging from the degree of
mutational damage, HERV-T sequences integrated in a
human primate progenitor genome around 30 million years
ago [52]. MLLVs include the pig endogenous gammaretro-
viruses, PERV A, B, and C, several of which are infectious
and are a problem for xenotransplantation of porcine organs
to humans. The murine MLLV groups G1-3 also contain
structurally intact proviruses. Very little attention has been
paid to groups G1 and G2, while group G3 (“MLVs”) has
been thoroughly investigated. The number of references
regardingtheG3groupwouldbestaggering,andoutofscope
f o rt h i sr e v i e w .T h er e c e p t o r sa n dh o s tr a n g eo fg r o u p sG 1
and G2 are largely unknown. However, the GLN retroviruses
seem to have a tropism similar to ecotropic MLVs [15].
GroupG3isknowntocontainMLLVswithseveralenvelope-
determined tropisms, see, for example, [53–55].
2.2.3.KnownandProbableInstancesofTransspeciesTransferof
Gammaretroviruses. As seen in Figure 5, MLLVs can infect a
wide range of hosts. For example, the XPR1 receptor, which
is used by xeno- and polytropic MLVs, is common among
vertebrates [57, 58]. In some cases, prey-predator relations
probablycontributedtothetransmission[59].Inothercases,
there are no such known relations. The wide range of hosts is
reﬂected in the panorama of their receptors [55, 57, 58, 60–
65]. They are known to spread via several modes: often via
saliva (e.g., into wounds of ﬁghting animals) and sexual
contact[26,62,66–72].Moreover,chimpanzeesseemtohave
been infected with MLLVs from baboon and other primates
[59], while baboons and cats also have common MLLVs
[73]. Thus, MLLVs and similar gammaretroviruses have a
tendency to spread between vertebrates.
However, a barrier against spread to humans may be
the strong anti-α-galactosyl antibodies in humans, which
can neutralize viruses coming from species with diﬀerent
glycosylation patterns, like the mouse [74]. Once the virus
has entered the body, its sugars will follow the human
glycosylation pattern, and the virus will not any longer be
neutralized. Therefore, this barrier is not absolute.
A variety of other restrictions, like the APOBEC cytidine
deaminases [50, 75, 76], tetherin [53], and TRIMs [77–
79] also aﬀect retroviral spread between species. However,
restrictions may be as important within a natural host as
between hosts [80, 81]. The high XMRV replication in the
cellline22Rv1[82]andthereadygrowthofXMRVinLNCap
cells [83], both RNAse L-deﬁcient human prostate cancer
cell lines, plus the ability to grow in human PBMCs [84],
indicate the ability of XMRV to grow in human cells [84]
and the importance of an intact interferon system for the
defence against it. These barriers to spread could probably be
overcome, and humans be infected by XMRV, although the
infectivity in vivo is hard to predict. It was recently reported
that XMRV can grow in human PBMCs [84].
Judging from the wide spread of MLLVs, a zoonotic
spread of XMRV/HMRV from mouse to human, directly or
indirectly via another vertebrate, is not impossible. Humans
are occasionally exposed to animals which harbor MLLVs.
For example, microbes known to spread to humans from
pets are viruses (arena-, hanta-, pox-, orthomyxo-, and
rhabdoviruses), bacteria (chlamydiae, salmonella, tularemia,
and leptospira), protozoa (toxoplasmosis), and helminths
(worms). Rabbits, mice, rats, and guinea pigs are frequent
as pets. The frequency of animal contact should therefore be
recordedinepidemiologicalinvestigationsregardingMLLVs,
like XMRV/HMRV, in humans.
Like other MLLVs, a human MLLV would be expected to
spreadviakissing,sex,intravenousdruguse,blooddonation,
and possibly via breast feeding. Enough systematic tests for
MLLVs in the corresponding body ﬂuids have not been
performed. There should also be an overrepresentation of
XMRV/HMRV in intravenous drug users and in patients
infected with other sexually transmitted microbes, like HIV
[85, 86]. This needs more study. Credible transmission
chains between ME/CFS patients (with the exception of
outbreaks), between PC patients, from ME/CFS to PC, and
from PC to ME/CFS have not been reported (cf. Table 1).
3 .D idM L L VSp r eadZ oo no tic all yt oH um ans ?
Gammaretroviruses related to the MLV were found 2006
in a few percent of patients suﬀering from prostate cancer
[9]. They were initially named XMRV. In 2009, XMRV
was also found in patients suﬀering from ME/CFS [6]. In
2010, the term XMRV was replaced with HMRV, because
gammaretroviral sequences found in ME/CFS were found to
b em o r ed i v e r s et h a nj u s tX M R V[ 56].
3.1. The Findings in PC. In 2006, Urisman et al. reported the
discovery of a novel retrovirus in a subpopulation of prostate
cancer patients in the United States [1, 8, 9]. Using ﬂuores-
cent in situ hybridization, the viral nucleic acid was located
to stroma cells, not the cancer cells. However, others found it
also in the cancer cells [110]. This retrovirus was identiﬁed
by means of a DNA microarray (“Virochip” [8, 9, 111])
screening of known cancer samples. The DNA microarray
contained 11 000 pieces of 70bp long oligonucleotides from
approximately 950 evolutionarily conserved viral genome
sequences. It has been used to screen for the presence of
viral DNA and also identify which family the detected virus
belongs to. Its success is a practical demonstration of the
utility of a phylogenetically directed search for new viruses.
The prostate cancer results are covered by other reviews in
this volume. Only selected data will be discussed here.
3.1.1. If XMRV/HMRV Is Not Situated in Cancer Cells,
How Could it Contribute to PC? MLLVs are not associated
with prostate cancer in animals. Therefore, the existence ofAdvances in Virology 7
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Figure 4: gag sequences of 300 high scoring mouse gammaretroviral sequences were aligned together with reference sequences. MLV
sequences with ascribed tropism, from GenBank, were also added. The tree was rooted with a divergent rabbit gammaretrovirus-like
sequence from scaﬀold 34, position 34101473 (oryCun1 assembly). Sequences in red (“HMRV”) are from the paper of Lo et al. [56]. They
were from ME/CFS patients (“CFS”) or blood donors (“BD”). Two blood donor sequences from the Lo et al. study came out at the base of
group G2, in other trees (not shown) at the base of group G3. The other emerged in group G3. The branch labels are either ERV host genus,
chromosomal position, provisional genus (“C”: gamma), and ReTe score, or a reference Pol name. Genomic ERV sequences taken from the
prototype of RetroBank were named as oryCun: rabbit, cavPor: guinea pig, felCat: cat, panTro: chimpanzee, or rheMac: rhesus macaque.
Mouse sequences are just shown with their chromosomal location.8 Advances in Virology
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Figure 5: MLLVs have spread among vertebrates in recent evolutionary time. The approximate time estimates to the last common MLLV
progenitor are based on references given in the text, and on the phylogenetic analysis of Figure 1.S o m eg i b b o na p e si nc a p t i v i t yh a v eg i b b o n
ape leukemia virus (GaLV). Koalas have recently been infected with koala retrovirus (KoRV). More distant relatives of the murine MLVs
occur in pigs and cats. Porcine MLLV ERVs (PERVs) are MLLVs but the interspecies transmission routes are uncertain. Cats have several
endogenous and exogenous MLLVs, including feline leukemia virus (FeLV). Birds have recently been infected with reticuloendotheliosis
virus (REV). REV is not strictly an MLLV, but is a gammaretrovirus highly related to MLLVs. Its origin is uncertain, but its closest relatives
are the ERV-T-like proviruses from opossum and primates. Humans may also recently have been infected with murine MLLVs, namely
XMRV, although there are now indications that this is a laboratory contamination with the 22Rv1 virus. Endo-: endogenous retrovirus.
Exo-: exogenous retrovirus.
an MLLV in human prostate cancer is unexpected. Initial
reports indicated that the retrovirus was integrated into
stromal cell ﬁbroblasts in the prostate cancer samples. This
could present a problem for the hypothesis that the newly
discovered virus is part of the oncogenic process. However,
it is generally accepted that there are close interactions
between the epithelial cells and the underlying stromal cells,
such as ﬁbroblasts, smooth muscle cells, endothelial cells
in blood vessels, and pericytes, both in normal tissue and
in tumours [112, 113]. This interaction consists of both
paracrine signalling and interactions with the extracellular
matrix, which in vivo have been shown to have a signiﬁcant
impactonthegrowthoftransformedcells.Itwasshown1966
that polyoma-infected epithelial and stromal cells would
not transform unless grown in contact with the underlying
stroma [114, 115]. It has also been shown in both in vivo and
in vitro studies that tumour-associated ﬁbroblasts contribute
to the transformation of immortalized epithelial cells [116],
indicating that there are permanent changes in the stromal
cells in tumours. What is even more interesting is that it has
been shown that the tumour-associated ﬁbroblasts can cause
nontumourigenic prostate epithelial cell lines to transform
if cocultured [117]. Thus, one cannot dismiss an MLLV as
being uninteresting with regard to tumourigenesis in the
prostate.
3.2. The Findings in ME/CFS. The main symptom of CFS is
a persistent and debilitating fatigue with rapid onset. It often
commencesafteranepisodeofinﬂuenza-likesymptoms.The
aﬄicted patients were previously healthy [87]. The symp-
toms include fatigue, loss of memory or concentration, sore
throat, painful lymphadenopathy, muscle pain, headache,
unrefreshing sleep, and extreme exhaustion after exercise.
The cause of CFS is not yet known. It is in need of clinical
and laboratory studies for its further deﬁnition. ME/CFS
can, however, be diagnosed according to internationally
accepted clinical criteria, see, for example, [118]. It seems
to be a rather common disease, maybe amounting to 0.5%
of the population [118]. Finding the cause, new diagnostic
techniques, and, hopefully, a cure, for this often debilitating
disease is a high medical priority. ME/CFS borders tothe dis-
eases ﬁbromyalgia (FM) and irritable bowel syndrome (IBS).
FM-like chronic pain and IBS-like intestinal symptoms are
common in ME/CFS [119].
In 2009, Lombardi et al., in Judy Mikovits’ group,
reported the discovery of the XMRV virus, using PCR andAdvances in Virology 9
Table 1: How well does XMRV/HMRV fulﬁll the expected properties of an MLV spread to humans + means an argument for, and—an
argument against expectation?
Property Expected ﬁnding Observed Conclusion, for or against
XMRV/HMRV in humans?
+Hybridization array w. conserved viral 70-mers, an
insensitive technique [9].
+Serendipitous.
For?
Viral nucleic acid
+PCR (positive, XMRV [87], positive, HMRV [56]a n d
−negative [3, 85, 88–100]r e s u l t s ) .
−Proven or suspected contamination w 22Rv1-like virus
and mouse DNA [3, 57, 93–96, 99–101].
Against?
+Integration into host genome [8].
−Some of the integration sites occur in an XMRV-infected
cell line [99].
Against?
Discovery/followup
+Cloning of XMRV into infectious clone (PC, ME/CFS)
[8].
−High sequence similarity and unique recombination
suggest contamination with DNA from XMRV producing
cell line [2].
Against?
Virus isolation
+Virus isolation (ME/CFS patients) [6, 102, 103].
−High sequence similarity, lack of evolution, and unique
recombination suggests contamination from XMRV
producing cell line [2, 82].
−Isolation results cannot be reproduced [3].
Against?
Antiviral immune
response
+SFFV FACS (ME/CFS) concordance with PCR outcome
[6, 102],
+ELISA (PC, ME/CFS), positive [104]a n d
−negative [84, 92, 105–107]o u t c o m e s ,
−Virus neutralization, negative outcome [90],
−Western blot (ME/CFS) negative outcome [105, 108],
−CMIA (ME/CFS), negative outcome [109],
−T-cell response, negative outcome [86].
Against?
Epidemiology, early
phase Contact with mouse Not observed/reported Against?
Epidemiology, late
phase
Human-human spread,
via saliva, sex, and
mother-child
−Although occasional ME/CFS outbreaks occur, most
cases are sporadic, with no spread between spouses.
−No reported epidemiological link between prostate
cancer and ME/CFS
−N ok n o w no v e r r e p r e s e n t a t i o ni nS T Da n di nI V D U[ 85].
Against?
Pathogenesis
Leukemia, lymphoma Prostate cancer?
F o ro ra g a i n s t ?
Immunodeﬁciency Immunodeﬁciency?
Encephalitis (MAIDS) Myalgic encephalomyelitis?
Enteritis (MAIDS, FAIDS) Irritable bowel syndrome?
Autoimmunity Thyroiditis?
Replication Relatively easy to detect in
blood Hard to detect in blood. Against?
Immune response Strong B-cell response,
positive WB Weak or absent B-cell response. Against?
serology, in 67% of chronic fatigue syndrome (ME/CFS)
patients compared to 3.7% in healthy controls [6]. Reports
which verify [56, 102, 103] and do not verify [84, 88–
93, 105, 106, 108, 120] the original ME/CFS report have
come. The situation is volatile and cannot be extensively
covered here. The conﬂicting results may be due to method-
ological diﬀerences, an uneven geographic distribution of
XMRV/HMRVs, or viral genetic variation. Switzer et al.
used a Western blot with a lysate from MLV, another
group G3 virus, to examine antibody response in 51CFS
patients and 53 healthy donors. No speciﬁc reaction was seen
[105].10 Advances in Virology
In a UK study involving 170CFS patients as well as 395
non-CFS patient controls, 4.6% of the samples contained
neutralizingantibodies,butonlyoneofthesewasfromaCFS
patient. Most of these positive sera were able to neutralize
MLV virus particles pseudotyped with Env-proteins of other
virusesindicatingsigniﬁcantcrossreactivity[90].Hohnetal.
searched for antibody activity of 36CFS and 112MS patients
and 27 healthy controls using an Env-ELISA and a capture
Gag-ELISA. No evidence of speciﬁc seroreactivity was found
[84].
3.2.1. Could an MLLV Cause the Combination of Neuro- and
Immunopathology Which Occurs in ME/CFS? MLLV infec-
tions are sometimes associated with immunosuppression
[121]. ME/CFS patients have a degree of immunosuppres-
sion, neurological symptoms, and often an enteritis. Giardia
has been associated with ME/CFS [122, 123]. Mice with
MAIDS are especially sensitive to intestinal parasites like
Giardia, a similarity which may be fortuitous [122, 123].
Likewise, cats with FAIDS are also immunosuppressed and
develop enteritis. Although such correlations are diﬀuse and
may be spurious they indicate that infectious agents could
give ME/CFS-like disease.
3.3. Other Diseases Expected to Occur If There Is an Infectious
Human Gammaretrovirus. Murine and feline diseases where
MLLVs are known to play a major role are leukemia,
lymphoma and encephalitis (and other neurological dis-
eases) and, as mentioned, immunodeﬁciency [124–132].
Autoimmune disease has also been linked to MLLVs [133,
134]. MLLVs should thus be searched for in these diseases.
So far, studies of associations of XMRV/HMRV with such
human diseases have not been published.
3.4.CanPhylogenyDirectOurEﬀortstoDetectMLLVInfection
in Humans?
3.4.1. Viral Nucleic Acid Detection. Nested PCRs have been
used in several of the positive XMRV reports. Such PCRs
have a high sensitivity, but also a high risk of amplicon
contamination.
The lower sensitivity of microarray analysis makes it
less susceptible to contamination. This makes the initial
serendipitous observation of XMRV in prostate tissue [9]
especially credible. Although PCRs are more sensitive, they
may miss imperfectly matching targets. High sensitivity also
means high risk of contamination. Amplimers, synthetic
sequences, and plasmids containing target sequences are
notorious problems. However, also genomic DNA harboring
target sequences (ERVs) is a problem. Mouse DNA is a
special case, because it contains many HMRV PCR target
sequencespercopyofmousegenome(seeabove).Thus,each
XMRV/HMRV PCR should be evaluated for its detection
range and tendency to give false positive results due to
mouse DNA contamination. Several of the PCRs which have
been used to detect XMRV react also with mouse DNA.
Some, like the integrase-based PCR of Ila Singh [135], do
not react with mouse DNA unless the DNA is present in
high concentration. Others react strongly with mouse DNA.
Mouse DNA contains at least two sequences which are
highly similar to XMRV, with ORF in gag, pro, pol and
env: Proviruses at chromosome 1, position 172778230 and
chromosome 5, position 23221036. The similarity is obvious
in pol and env,l e s ss oi ngag (mouse genome assembly mm8,
which comes from C57Black). These proviruses are situated
next to XMRV VP62 in the Pol-based tree in Figure 3.A l l
broadly targeted (“HMRV-speciﬁc”) PCRs react with mouse
DNA, while some “XMRV speciﬁc,” like the Singh PCR, do
not react, or react only with high amounts of mouse DNA
(Elfaitouri et al., submitted). Among 30 vertebrate genomic
DNAs analyzed bioinformatically, mouse DNA is most likely
to give such spurious PCR signals (Blomberg and Elfaitouri,
unpublished).
A test which lends high credibility to a positive provirus
detection is if integration sites in the host genome can be
cloned and sequenced. This has been reported for XMRV in
PC [7]. However, Garson et al. [99] claimed that integration
sites in 2 of 14 prostate cancer patient samples reported
from Silverman’s group [8, 9] were identical to those of the
experimentally infected human tumour cell line DU145 used
in the same laboratory. This raises the possibility that this
ﬁnding is due to contamination.
The Problem of Mouse DNA and XMRV DNA Contamina-
tion. Where Does It Come from? Several laboratories have
reported frequent occurrence of mouse DNA in samples
from humans. Some of the PCRs used for detection of
XMRV/HMRV also become positive when mouse DNA is
present, because (as explained earlier in this review) the
mouse genome contains many proviruses which react in
these PCRs. However, some XMRV PCRs do not react with
mouse DNA [110]. They should be less likely to give false
positive signals due to presence of mouse DNA. Presence of
mouse DNA in human samples may sound absurd and is
often not easy to explain. It may be caused by contamination
of chemicals and biologicals used to prepare the samples.
For example, mouse DNA may be present on microtomes
used for preparation of tissue sections from both mouse and
humans. Further, some cell lines (especially hybridomas of
mouse origin) contain high amounts of XMRV or related
MLVs and can contaminate other cell lines [136, 137].
It is therefore logical that murine monoclonal antibodies,
including anti-Taq polymerase antibodies, which are used
to provide a “hot” start in PCRs, sometimes contain traces
of nucleic acid from MLVs [101]. Moreover, the highly
XMRV producing cell line 22Rv1 contains a virus which is
very similar (essentially identical; see Figure 4)t or e p o r t e d
XMRVs [99]. It is a human prostate cancer cell line which
was infected with XMRV during passage in nude mice
[2]. According to recent information, XMRV arose by a
unique recombination event between two defective MLV
sequences [2]. It is therefore reasonable to assume that
XMRV originated from the 22Rv1 virus which then has been
a contamination source of many of the published positive
resultsfromprostatecancerandME/CFS.Infact,allcelllines
w h i c hh a v eb e e np a s s e di nn u d eo rS C I Dm i c es h o u l db e
suspected of retroviral contamination.Advances in Virology 11
If contamination explains all positive PCR results in
ME/CFS and prostate cancer, why would the frequency
in ME/CFS patients be at least tenfold higher than in
the controls? The patient samples may have been more
frequently opened than the control samples. At least two
kinds of contamination, with mouse and XMRV DNA,
respectively, have to be invoked. Although false positive
PCR results due to contamination in the laboratory is a
frequent event, contamination on such a grand scale is
beyond previous experience.
TherearesimilaritiesbetweentheXMRV/HMRVandthe
“Human Retrovirus 5” (HRV5) stories [138]. HRV5 is one
of the so-called “rumor viruses” [139]. It turned out to be
a defective rabbit betaretrovirus (RERV-H) whose DNA is
abundant in rabbit sera [140] .T h er a b b i tg e n o m ec o n t a i n s
around 700 copies of RERV-H [140]. Any laboratory which
handles rabbit sera is at risk of RERV-H contamination. In
analogy with this, a low level of mouse (or XMRV) DNA
couldbepresentinlaboratoryreagents,cellcultures,orinthe
laboratory environment, as evidenced by many conﬁrmed
reports of contamination, or unconﬁrmed reports of human
retroviruses [73, 93–96, 99–101, 136, 137, 141–165]. Thus,
extensive contamination controls must be performed if PCR
is used for detection of XMRV/HMRV.
3.4.2. Viral Reverse Transcriptase Detection. Reverse tran-
scriptase (RT) activity is a fundamental and conserved func-
tion of retroviruses. Detection of RT activity is an established
method for retrovirus discovery and diagnosis. There is an
evolutionary limit to the extent to which the enzyme can
mutate. Presence of signiﬁcant retroviral RT activity in a bio-
logical sample is thus not only an indication of virus protein
expression, but of retrovirus replication. RT activity assays
thus give an additional dimension compared to detection
of viral nucleic acids or proteins. The RT enzymes from
diﬀerent retroviruses have diﬀerent enzymatic properties.
By varying pH and the composition and concentrations of
certain components, it is possible to optimize assays for a
virus family or subgroup [166]. RT assays can also be per-
formed with PCR readout, which gives a very high sensitivity
[167, 168]. Quantiﬁcation of RT activity may be complicated
by a myriad of RT inhibitory factors and requires enzyme
puriﬁcation. A simple colorimetric RT activity assay [166]
can be used both for monitoring propagation of XMRV
virus in cell culture and for direct detection in samples
from humans [169]. RT assays are somewhat less sensitive
than PCR and have less problems with contamination and a
broader detection range. An RT assay optimized for XMRV
has been developed (http://cavidi.se/). It has a minimum
level of detection of 0.01μU RT activity, which corresponds
to approximately 50 virus particles per reaction (Elfaitouri
et al, accepted for publication in Plos One). It is currently
usedasanindependenttechniqueforfollowingisolationand
propagation of MLV-related viruses in our laboratory.
3.4.3. Virus Isolation. The Mikovits group at the Whittemore
Peterson Institute reported a high frequency of virus
isolation from ME/CFS patients [6, 102, 103]. We are not
aware of a report on XMRV isolation from prostate cancer
patients. Virus isolation is inherently less susceptible to
contamination than PCR is, because retroviruses are easy to
disinfect. They also lose infectivity after drying. The virus
isolation results are therefore the mainstay of the proponents
of XMRV [102, 103]. An especially eﬃcient and speciﬁc
virus isolation test seems to be the DERSE (detector of
e x o g e n o u sr e t r o v i r a ls e q u e n c e s )a s s a y[ 170]. The isolation
results from ME/CFS patients were recently contested [3].
Patients which earlier were reported to be XMRV isolation
positive were found to be negative on retesting. This raises
the possibility that also the virus isolation results were due
to contamination with 22Rv1 tissue culture virus. The 22Rv1
virus is present in billions of copies per mL of tissue culture
supernatant. Retroviral contamination of cell cultures is
common, see, for example, [136, 137, 171]. Low or moderate
expression of potentially infectious ERVs in cell culture is a
particularly vexing problem [137, 143, 172–176].
3.4.4. Serology. Antigens for use in XMRV/HMRV serology
range from synthetic peptides to recombinant proteins. In
this situation, cross-reactive epitopes in Gag and trans-
membrane proteins are of special interest. Epitopes from,
primarily, Env and Gag proteins of XMRV and related MLVs
should be covered. It is fortunate that much information
regarding B-cell epitopes is available for MLVs and FeLVs
(against which an eﬀective vaccine exists). It can guide the
selection of synthetic peptides. Synthetic peptides, primarily
mimicking linear epitopes, have been useful for development
of serological assays for detection of other retroviruses such
as HIV and HTLV [177–182]. However, an optimal sero-
logical assay should cover both linear and conformational
epitopes. Whole virus [105, 109, 183, 184], recombinant
XMRV proteins [84, 104, 106, 109, 183, 185], and a
“surrogate” spleen focus forming virus (SFFV) ﬂuorescence-
activated cell sorter (FACS) antibody test [6]h a v eb e e n
used. SFFV has an envelope which is a recombinant between
the envelopes of the infectious Friend helper virus and an
endogenous polytropic virus. It also has a large deletion
involving the SU/TM cleavage site. Cells with and without
transduced SFFV envelope are incubated with serum and
ﬂuorescent antihuman IgG and then run in an FACS.
This is an elegant and speciﬁc technique, but is dependent
on a few cross-reactive envelope epitopes. Western blot
(WB) using whole virus (or a set of recombinant proteins)
[105]i sade facto serological golden standard in clinical
retrovirology. It would be desirable to have a conﬁrmatory
WB assay for serological XMRV diagnosis. Screening assays
could be existing enzyme immunoassays (EIAs), suspension
arrays [120], or chemiluminescent magnetic microparticle
immunoassays (CMIA) [109]. Neutralization assays [89]
can be highly speciﬁc, but may be too narrow if a broad
search is desired. The FACS analyses of antibodies binding to
SFFV envelope transduced cells should also be very speciﬁc.
None of the latter two are, however, suitable for large-scale
screening. There is a long history of serological ﬁndings of
gammaretrovirus antibodies and antigens in human disease
[73, 186–203]. Given the tendency of serological methods to
cross-react,weakserologicalreactionstoafewepitopesalone
are not strong evidence.12 Advances in Virology
A serological diagnosis of a retroviral infection needs
demonstration of an immune response at several epitopes.
It cannot be the only serological evidence. Ideally, several
tests with diﬀerent speciﬁcities, covering both broadly cross-
reactive and speciﬁc, linear and conformational, epitopes
should be used. Several of these serological assays are
capableofdetectingantibodyreactivitytootherMLVs.Thus,
although it may not be intentional, the intense hunt for
XMRV antibodies is also a hunt for other MLLVs in humans.
The largely negative outcome [84, 105, 106, 108, 204]m a y
be taken as evidence against widespread MLLV infection in
humans.
3.4.5. Why Was XMRV/HMRV Not Discovered in the Virus
Cancer Program during 1964–1977? Ac o n s i d e r a b l eU Se ﬀort
toﬁndnewretroviruseswastheVirusCancerprogram[205].
Virus isolation and reverse transcriptase assays were main
techniques.MLVandsimilarvirusesarerelativelyeasytocul-
tivate. They were known at the time and were also main tar-
gets for the program. It is therefore notable that such a virus
was not detected in humans with cancer during this project.
Reasons could be manifold, either due to bad luck, inappro-
priate methods, due to an introduction of XMRV/HMRV
into humans, or spread of a tissue culture contaminating
virus after the conclusion of the Virus Cancer program.
3.4.6. Summary of Current Controversies Regarding XMRV/
HMRV. Since the initial reports of XMRV in US patients
with prostate cancer and CFS, several research groups have
been attempting to replicate these results. Especially, the
connection of XMRV to CSF has raised considerable interest
in this virus. However, it has not been possible to detect the
virus in studies from China where Hong et al. have analyzed
samples from 65CFS patients and 85 healthy controls [92],
from Netherlands where van Kuppeveld et al investigated
samples from 76CFS patients and 69 matched controls
[98], from UK where Groom et al. tested samples from
170CFS patients and 395 non-CFS control patients [90],
andErlweinetal.investigatedsamplesfrom186CFSpatients
[89], and from the US where Switzer et al. analyzed samples
from 51CFS patients and 53 healthy controls [105], using
either PCR-based methods for detecting viral RNA/DNA or
methodsfordetectingneutralizingantibodiesagainstXMRV.
Hohn et al. were likewise unable to detect XMRV in any of
the 589 German prostate cancer samples they analyzed for
thepresenceofXMRV[84,106].Tofurtherconfusetheissue,
a US research group failed to detect the XMRV itself but was
able to detect viral sequences closer related to other MERVs
(“HMRV”; here shown to belong to group G3 MLLV) in a
retrospective study of blood samples from CSF patients [56].
3.4.7. An Attempt to Reconcile Current Results Regarding
XMRV/HMRV with Each Other.
WhyIsXMRV/HMRVSoHardtoDetectbyPCRandSerology?
Apossibilitywhichcouldreconciliatetheconﬂictingﬁndings
could be that a chronic XMRV/HMRV infection becomes
progressively harder to detect both by nucleic acid, virus
isolation, and serological methods. XMRV/HMRV would
then establish a low-grade infection in a limited number
of cell types, with a waning immune response. This is
reminiscent of what was seen in experimentally XMRV-
infected macaques [109, 183]. The dynamics of antibody
response elicited by XMRV were studied in ﬁve XMRV-
infected macaques. Using recombinant gp70, p15E, and p30
in western blots and CMIA, Qiu et al. found evidence
of antibodies two weeks after infection. The antibodies
persisted for at least 158 days. Although all three proteins
elicited an immune response, antibodies to recombinant
gp70 and p15E showed higher sensitivity than p30 [109,
183]. The Western blots were very clear. Such XMRV
Western blots were never reported from humans. There
was a tendency for the antibody levels to decrease over
time. Stimulation with a dose of XMRV antigen gave
rise to a burst of viral replication and a rise in XMRV
antibodies. In another study, Mus pahari was experimentally
infected with XMRV [184]. Antibodies to XMRV Env (p15E
and gp70) and Gag (p30) were detected in Western blots
and in ELISA tests. Neutralizing antibodies also devel-
oped.
Thus, the expected course of an XMRV/HMRV infection
is an initial phase with intense viral replication, easily
detected by PCRs on nucleic acids from plasma or PBMCs,
followed by development of a strong antibody response
which can be demonstrated by several kinds of serology,
and a full WB pattern, similar to the situation during HIV
infection.
However, the diﬃculties of ﬁnding both viral nucleic
acid in blood samples and a weak or nonexistent antibody
response in virus isolation or XMRV/HMRV PCR-positive
persons lead us to two alternate interpretations.
First, we must hypothetically consider a model of low-
grade chronic XMRV/HMRV infection of humans. Such a
“stealth” infection could have similarities with ERVs. The
immune response to ERVs is abnormal, possibly because
they are perceived as “self” by the adaptive immune system
[206]. Theirprotein expression may alsobeweak. Inputative
“stealth” non-ERV RV infection a low degree of continuous
antigenic stimulation could lead to a low, and waning
immune response [207]. Although a vigorous antibody
response is the most common reaction to a retrovirus
infection, a very weak antibody response is also seen in some
cases of HLTV-2 infection, which can also be accompanied
by a low degree of viral replication [208, 209]. It is a
considerablediﬃcultyforthediagnosisofHTLV-2infections
in humans by PCR and serology. Likewise, HIV patients
which were treated early during the infection may develop
an abortive immune response [210, 211]. It is conceivable
that the XMRV/HMRV situation could be similar. There are
aspects of the MAIDS/FAIDS models which ﬁt with ME/CFS
and this model.
The second alternative is that all reports of XMRV/
HMRV in humans have been due to contamination or
serological cross-reaction. The PCRs could have been con-
founded by various forms of contamination (see below).
The positive serologies in ME/CFS patients have largely been
fromthesurrogateSFFVFACSantibodytest[6],whichaloneAdvances in Virology 13
does not fully suﬃce as evidence. It would be a sad outcome
of a fascinating and important story.
3.5. Medical and Ethical Consequences of the Uncertain Diag-
nostic Situation. The ﬁnding of XMRV/HMRV in ME/CFS
has far-reaching implications, for the personal life of the
patients (sex, kissing, breast feeding, etc.), for the develop-
ment of diagnostic methods, for transfusion safety, and for
the understanding of other human diseases with a possible
retroviral etiology. It is reasonable to demand that measures
to protect blood transfusion recipients from infection are as
rigorous as the sensitivity and speciﬁcity of available tests
allow. In the situation of today, where the reported frequency
of XMRV infection found with diﬀerent methods in blood
donors or comparable healthy individuals varies from 0 to
7%, there is no simple test strategy available. However, the
mere suspicion that a retrovirus like XMRV is frequent in
patients suﬀering from ME/CFS is a basis for abstaining
from using such patients as blood donors [212]. The ﬁnding
of XMRV in PC also raises medical and ethical questions.
However, the frequency of positivity is at a few percent, and
claims of a connection have not reached the high frequencies
reported in ME/CFS (>60%).
Both ME/CFS and PC patients suﬀer from the uncer-
taintyregardingXMRV/HMRVpositivityinthetwodiseases.
The patients must make personal decisions regarding sexual
contacts, kissing, and breast milk feeding of their children.
Few PC patients will know their alleged XMRV/HMRV
status, but the rather widespread testing of ME/CFS patients
for this virus has created a group of patients who are left
in limbo. The temptation to start antiretroviral treatment
[213] despite the current scientiﬁc controversy can be hard
to resist.
4. Conclusions
Research on XMRV/HMRV in humans is evolving rapidly.
There is a great need for conﬁrmation of the reports on
XMRV/HMRVs in PC and ME/CFS. In view of the recently
demonstrated diversity of retroviral sequences in ME/CFS,
it is also important to establish the detection range of
XMRV/HMRV detection methods. Contamination of cell
cultures with 22Rv1 virus and PCRs with MLV nucleic acid
and mouse DNA is known to occur. Whether all reports on
MLLVsinhumanscanbeexplainedbythemisuncertain,but
not unlikely. The XMRV/HMRV story has both credible and
less credible aspects (Table 1). The original XMRV detection
in prostate cancer was serendipitous and made with several
independent techniques, together forming a credible case.
The proven integration into human DNA was especially
convincing. The ﬁnding of XMRV/HMRV in ME/CFS also
has a credible aspect; the immunomodulating properties of
MLLVs could theoretically explain the disease. However, the
epidemiology of XMRV/HMRV transmission still is unclear.
The absence of an easily measurable immune response is also
a memento.
We conclude that MLLVs are widespread as ERVs
among vertebrates. There are many signs of interspecies
transmission of MLLVs. However, only a few of the MLLVs
are structurally intact. The mouse genome is unique in
its high content of MLLVs. It contains three major MLLV
groups, of which two (G1 and G2) have not hitherto been
reported. Group G3 contains the MLVs and all or nearly all
of the MLV-like retroviruses which have so far been detected
in humans, that is, XMRV and HMRV.
The study of XMRV/HMRV is important from a range
of perspectives, one of which is screening of blood donors
for potentially harmful pathogens. Xenotropic viruses also
raiseconcernsregardingresearchintoxenotransplantationof
organs [16].
The detection of human infection with XMRV/HMRV
has proven to be diﬃcult. This may either be due to
absence of the virus or to a low-grade infection, with a
minimalviralreplicationandaminimalserologicalresponse.
Although that goes contrary to expectations, such a situation
sometimes occurs in HTLV and HIV infections.
Acknowledgments
The ﬁnancial support from ME Research UK (Charity no.
SC 036942), the Irish ME Trust, and Stiftelsen Lars Hiertas
Minne (FO2010-0672) is gratefully acknowledged.
References
[ 1 ]K .L e ea n dK .S .J o n e s ,“ T h ep a t hw e l lt r a v e l e d :u s i n gm a m -
malian retroviruses to guide research on XMRV,” Molecular
Interventions, vol. 10, no. 1, pp. 20–24, 2010.
[2] T. Paprotka, K. A. Delviks-Frankenberry, O. Cingoz et al.,
“Recombinant origin of the retrovirus XMRV,” Science, vol.
333, no. 6038, pp. 97–101, 2011.
[3] K. Knox, D. Carrigan, G. Simmons et al., “No evidence of
murine-like gammaretroviruses in CFS patients previously
identiﬁed as XMRV-infected,” Science, vol. 333, no. 6038, pp.
94–97, 2011.
[4] R. H. Silverman, C. Nguyen, C. J. Weight, and E. A.
Klein, “The human retrovirus XMRV in prostate cancer and
chronic fatigue syndrome,” Nature Reviews Urology, vol. 7,
no. 7, pp. 392–402, 2010.
[5] H. G. Klein, R. Y. Dodd, F. B. Hollinger et al., “Xenotropic
murine leukemia virus-related virus (XMRV) and blood
transfusion: report of the AABB interorganizational XMRV
task force,” Transfusion, vol. 51, no. 3, pp. 654–661, 2011.
[ 6 ]V .C .L o m b a r d i ,F .W .R u s c e t t i ,J .D .G u p t ae ta l . ,“ D e t e c t i o n
of an infectious retrovirus, XMRV, in blood cells of patients
with chronic fatigue syndrome,” Science, vol. 326, no. 5952,
pp. 585–589, 2009.
[ 7 ]S .K i m ,N .K i m ,B .D o n ge ta l . ,“ I n t e g r a t i o ns i t ep r e f e r e n c e
of xenotropic murine leukemia virus-related virus, a new
human retrovirus associated with prostate cancer,” Journal of
Virology, vol. 82, no. 20, pp. 9964–9977, 2008.
[8] B. Dong, S. Kim, S. Hong et al., “An infectious retrovirus
susceptible to an IFN antiviral pathway from human prostate
tumors,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 104, no. 5, pp. 1655–1660,
2007.
[9] A. Urisman, R. J. Molinaro, N. Fischer et al., “Identiﬁcation
of a novel gammaretrovirus in prostate tumors of patients
homozygous for R462Q RNASEL variant,” PLoS Pathogens,
vol. 2, no. 3, article e25, 2006.14 Advances in Virology
[10] J. Denner, “Detection of a gammaretrovirus, XMRV, in the
human population: open questions and implications for
xenotransplantation,” Retrovirology, vol. 7, article 16, 2010.
[11] P. Schmidt, A. Forsman, G. Andersson, J. Blomberg, and
O. Korsgren, “Pig islet xenotransplantation: activation of
porcine endogenous retrovirus in the immediate post-trans-
plantation period,” Xenotransplantation,v o l .1 2 ,n o .6 ,p p .
450–456, 2005.
[12] P. Schmidt, G. Andersson, J. Blomberg, A. Malmsten, and
O. Korsgren, “Possible transmission of zoonoses in xeno-
transplantation: porcine endogenous retroviruses (PERVs)
from an immunological point of view,” Acta Veterinaria
Scandinavica, vol. 99, supplement, pp. 27–34, 2004.
[13] L. Bromham, F. Clark, and J. J. McKee, “Discovery of a novel
murinetypeCretrovirusbydatamining,”JournalofVirology,
vol. 75, no. 6, pp. 3053–3057, 2001.
[14] G. Wolgamot, L. Bonham, and A. D. Miller, “Sequence
analysis of Mus dunni endogenous virus reveals a hybrid
VL30/gibbon ape leukemia virus-like structure and a distinct
envelope,” Journal of Virology, vol. 72, no. 9, pp. 7459–7466,
1998.
[ 1 5 ]D .R i b e t ,F .H a r p e r ,C .E s n a u l t ,G .P i e r r o n ,a n dT .H e i d -
mann, “The GLN family of murine endogenous retroviruses
contains an element competent for infectious viral particle
formation,” Journal of Virology, vol. 82, no. 9, pp. 4413–4419,
2008.
[ 1 6 ]Y .T .J u n g ,T .W u ,a n dC .A .K o z a k ,“ C h a r a c t e r i z a t i o no f
recombinantnonecotropicmurineleukemiavirusesfromthe
wild mouse species mus spretus,” Journal of Virology, vol. 77,
no. 23, pp. 12773–12781, 2003.
[ 1 7 ]C .H .T i p p e r ,C .E .B e n c s i c s ,a n dJ .M .C o ﬃn, “Character-
ization of Hortulanus endogenous murine leukemia virus,
an endogenous provirus that encodes an infectious murine
leukemia virus of a novel subgroup,” Journal of Virology, vol.
79, no. 13, pp. 8316–8329, 2005.
[ 1 8 ]M .S c h m i d t ,T .W i r t h ,B .K r ¨ oger, and I. Horak, “Structure
and genomic organization of a new family of murine
retrovirus-related DNA sequences (muRRS),” Nucleic Acids
Research, vol. 13, no. 10, pp. 3461–3470, 1985.
[19] Y. Zhao, C. P. D. Jacobs, L. Wang, and S. C. Hardies,
“MuERVC: a new family of murine retrovirus-related repet-
itive sequences and its relationship to previously known
families,” Mammalian Genome, vol. 10, no. 5, pp. 477–481,
1999.
[20] J. M. Yi, T. H. Kim, J. W. Huh et al., “Human endogenous
retroviral elements belonging to the HERV-S family from
human tissues, cancer cells, and primates: expression, struc-
ture, phylogeny and evolution,” Gene,vol.342,no.2,pp.283–
292, 2004.
[21] J. Blomberg, F. Benachenhou, V. Blikstad, G. Sperber, and
J. Mayer, “Classiﬁcation and nomenclature of endogenous
retroviral sequences (ERVs). Problems and recommenda-
tions,” Gene, vol. 448, no. 2, pp. 115–123, 2009.
[ 2 2 ] A .L .R o c a ,J .P e c o n - S l a t t e r y ,a n dS .J .O ’ B r i e n ,“ G e n o m i c a l l y
intact endogenous feline leukemia viruses of recent origin,”
Journal of Virology, vol. 78, no. 8, pp. 4370–4375, 2004.
[23] V. N. Kewalramani, A. T. Panganiban, and M. Emerman,
“Spleen necrosis virus, an avian immunosuppressive retro-
virus, shares a receptor with the type D simian retroviruses,”
Journal of Virology, vol. 66, no. 5, pp. 3026–3031, 1992.
[24] T. G. Kawakami, G. V. Kollias Jr., and C. Holmberg, “Onco-
genicity of gibbon type-C myelogenous leukemia virus,”
International Journal of Cancer, vol. 25, no. 5, pp. 641–646,
1980.
[25] T. G. Kawakami, L. Sun, and T. S. McDowell, “Natural
transmission of gibbon leukemia virus,” Journal of the
National Cancer Institute, vol. 61, no. 4, pp. 1113–1115, 1978.
[26] R. Tarlinton, J. Meers, and P. Young, “Endogenous retro-
viruses: biology and evolution of the endogenous koala
retrovirus,” Cellular and Molecular Life Sciences, vol. 65, no.
21, pp. 3413–3421, 2008.
[27] J.Martin,E.Herniou,J.Cook,R.W.O’Neill,andM.Tristem,
“Interclasstransmissionandphyletichosttrackinginmurine
leukemia virus-related retroviruses,” Journal of Virology, vol.
73, no. 3, pp. 2442–2449, 1999.
[28] J. M. Coﬃn, S. H. Hughes, and H. E. Varmus, Eds.,
Retroviruses, Cold Spring Harbor Laboratory Press, New
York, NY, USA, 1997.
[29] R. J. Gorelick, D. J. Chabot, D. E. Ott et al., “Genetic analysis
of the zinc ﬁnger in the moloney murine leukemia virus
nucleocapsid domain: replacement of zinc-coordinating
residues with other zinc-coordinating residues yields non-
infectious particles containing genomic RNA,” Journal of
Virology, vol. 70, no. 4, pp. 2593–2597, 1996.
[ 3 0 ]P .J e r n ,G .O .S p e r b e r ,a n dJ .B l o m b e r g ,“ U s eo fe n d o g e n o u s
retroviralsequences(ERVs)andstructuralmarkersforretro-
viral phylogenetic inference and taxonomy,” Retrovirology,
vol. 2, article 50, 2005.
[31] D. C. Aziz, Z. Hanna, and P. Jolicoeur, “Severe immunod-
eﬁciency disease induced by a defective murine leukaemia
virus,” Nature, vol. 338, no. 6215, pp. 505–508, 1989.
[32] Y. Kubo, Y. Nakagawa, K. Kakimi et al., “Presence of
transplantable T-lymphoid cells in C57BL/6 mice infected
with murine AIDS virus,” Journal of Virology, vol. 66, no. 9,
pp. 5691–5695, 1992.
[33] C. Simard, M. Huang, and P. Jolicoeur, “Establishment of
leukemic T-cell lines from mice inoculated with the MAIDS
defective virus,” Virology, vol. 206, no. 1, pp. 555–563, 1995.
[34] J. Overbaugh, N. Riedel, E. A. Hoover, and J. I. Mullins,
“Transduction of endogenous envelope genes by feline
leukaemia virus in vitro,” Nature, vol. 332, no. 6166, pp. 731–
734, 1988.
[35] J. L. Rohn, S. R. Gwynn, A. S. Lauring, M. L. Linenberger,
and J. Overbaugh, “Viral genetic variation, AIDS, and the
multistep nature of carcinogenesis: the feline leukemia virus
model,” Leukemia, vol. 10, no. 12, pp. 1867–1869, 1996.
[36] S. L. Roth, N. Malani, and F. D. Bushman, “Gammaretroviral
integration into nucleosomal target DNA in vivo,” Journal of
Virology, vol. 85, no. 14, pp. 7393–7401, 2011.
[37] F. D. Bushman, “Retroviral integration and human gene
therapy,” Journal of Clinical Investigation, vol. 117, no. 8, pp.
2083–2086, 2007.
[38] X. Wu, Y. Li, B. Crise, and S. M. Burgess, “Transcription start
regions in the human genome are favored targets for MLV
integration,”Science,vol.300,no.5626,pp.1749–1751,2003.
[39] S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt et al.,
“LMO2-associated clonal T cell proliferation in two patients
after gene therapy for SCID-X1,” Science, vol. 302, no. 5644,
pp. 415–419, 2003.
[ 4 0 ] C .H .J .L a m e r s ,R .A .W i l l e m s e n ,P .M .M .L .v a n
Elzakker, J. W. Gratama, and R. Debets, “Gibbon ape
leukemia virus poorly replicates in primary human T lym-
phocytes: implications for safety testing of primary human
TlymphocytestransducedwithGALV-pseudotypedvectors,”
Journal of Immunotherapy, vol. 32, no. 3, pp. 272–279, 2009.Advances in Virology 15
[41] S. Haraguchi, R. A. Good, G. J. Cianciolo, R. W. Engelman,
and N. K. Day, “Immunosuppressive retroviral peptides:
immunopathological implications for immunosuppressive
inﬂuences of retroviral infections,” Journal of Leukocyte
Biology, vol. 61, no. 6, pp. 654–666, 1997.
[ 4 2 ]M .N e l s o n ,D .S .N e l s o n ,G .J .C i a n c i o l o ,a n dR .S n y d e r m a n ,
“Eﬀects of CKS-17, a synthetic retroviral envelope peptide,
on cell-mediated immunity in vivo: immunosuppression,
immunogenicity, and relation to immunosuppressive tumor
products,” Cancer Immunology Immunotherapy, vol. 30, no.
2, pp. 113–118, 1989.
[43] M. Enserink, “Chronic fatigue syndrome. New XMRV paper
looks good, skeptics admit—yet doubts linger,” Science, vol.
329, no. 5995, p. 1000, 2010.
[44] M. Mangeney and T. Heidmann, “Tumor cells expressing
a retroviral envelope escape immune rejection in vivo,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 95, no. 25, pp. 14920–14925, 1998.
[45] G.Schlecht-Louf,M.Renard,M.Mangeneyetal.,“Retroviral
infection in vivo requires an immune escape virulence factor
encrypted in the envelope protein of oncoretroviruses,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 8, pp. 3782–3787, 2010.
[46] M. Yeager, E. M. Wilson-Kubalek, S. G. Weiner, P. O. Brown,
and A. Rein, “Supramolecular organization of immature
and mature murine leukemia virus revealed by electron
cryo-microscopy: implications for retroviral assembly mech-
anisms,”ProceedingsoftheNationalAcademyofSciencesofthe
UnitedStatesofAmerica,vol.95,no.13,pp.7299–7304,1998.
[47] J. Blomberg, G. Sperber, P. Jern, and F. Benachenhou,
“Towards a retrovirus database, retrobank,” in Proceedings of
the Centennial Retrovirus Meeting,R .D a n i e l ,J .H e j n a r ,A .
M. Skalka, and J. Svoboda, Eds., Medimond International
Proceedings, pp. 19–22, Prague, Czech Republic, 2010.
[48] G. O. Sperber, T. Airola, P. Jern, and J. Blomberg, “Auto-
mated recognition of retroviral sequences in genomic data—
RetroTector,” NucleicAcidsResearch,vol.35,no.15,pp.4964–
4976, 2007.
[49] G. Sperber, A. L¨ ovgren, N. E. Eriksson, F. Benachenhou,
and J. Blomberg, “RetroTector online, a rational tool for
analysis of retroviral elements in small and medium size
vertebrate genomic sequences,” BMC Bioinformatics, vol. 10,
supplement 6, article S4, 2009.
[ 5 0 ]P .J e r n ,J .P .S t o y e ,a n dJ .M .C o ﬃn, “Role of APOBEC3
in genetic diversity among endogenous murine leukemia
viruses,” PLoS Genetics, vol. 3, no. 10, pp. 2014–2022, 2007.
[51] L. M. Albritton, L. Tseng, D. Scadden, and J. M. Cunning-
ham, “A putative murine ecotropic retrovirus receptor gene
encodes a multiple membrane-spanning protein and confers
susceptibility to virus infection,” Cell, vol. 57, no. 4, pp. 659–
666, 1989.
[52] M. Haltmeier, W. Seifarth, J. Blusch, V. Erﬂe, R. Hehlmann,
and C. Leib-Mosch, “Identiﬁcation of S71-related human
endogenous retroviral sequences with full-length pol genes,”
Virology, vol. 209, no. 2, pp. 550–560, 1995.
[53] C. A. Kozak, “The mouse “xenotropic” gammaretroviruses
and their XPR1 receptor,” Retrovirology, vol. 7, article 101,
2010.
[54] J. P. Stoye and J. M. Coﬃn, “Polymorphism of murine
endogenous proviruses revealed by using virus class-speciﬁc
oligonucleotideprobes,”JournalofVirology,v ol.62,no .1,pp .
168–175, 1988.
[55] J. P. Stoye and J. M. Coﬃn, “The four classes of endogenous
murineleukemiavirus:structuralrelationshipsandpotential
for recombination,” Journal of Virology,v o l .6 1 ,n o .9 ,p p .
2659–2669, 1987.
[56] S. C. Lo, N. Pripuzova, B. Li et al., “Detection of MLV-
relatedvirusgenesequencesinbloodofpatientswithchronic
fatigue syndrome and healthy blood donors,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 107, no. 36, pp. 15874–15879, 2010.
[57] Y. Yan, Q. Liu, K. Wollenberg, C. Martin, A. Buckler-
White, and C. A. Kozak, “Evolution of functional and
sequence variants of the mammalian XPR1 receptor for
mouse xenotropic gammaretroviruses and the human-
derived retrovirusXMRV,”JournalofVirology,vol.84,no.22,
pp. 11970–11980, 2010.
[58] Y. Yan, Q. Liu, and C. A. Kozak, “Six host range vari-
ants of the xenotropic/polytropic gammaretroviruses deﬁne
determinants for entry in the XPR1 cell surface receptor,”
Retrovirology, vol. 6, article 87, 2009.
[59] P .J ern,G.O .Sperber ,andJ .Blomberg,“Divergentpatternsof
recent retroviral integrations in the human and chimpanzee
genomes: probable transmissions between other primates
and chimpanzees,” Journal of Virology,v o l .8 0 ,n o .3 ,p p .
1367–1375, 2006.
[60] M. Marin, D. Lavillette, S. M. Kelly, and D. Kabat, “N-linked
glycosylation and sequence changes in a critical negative
control region of the ASCT1 and ASCT2 neutral amino acid
transporters determine their retroviral receptor functions,”
Journal of Virology, vol. 77, no. 5, pp. 2936–2945, 2003.
[61] M. Marin, C. S. Tailor, A. Nouri, and D. Kabat, “Sodium-
dependent neutral amino acid transporter type 1 is an aux-
iliary receptor for baboon endogenous retrovirus,” Journal of
Virology, vol. 74, no. 17, pp. 8085–8093, 2000.
[62] M. P. Kavanaugh and D. Kabat, “Identiﬁcation and
characterization of a widely expressed phosphate trans-
porter/retrovirus receptor family,” Kidney International, vol.
49, no. 4, pp. 959–963, 1996.
[63] M. P. Kavanaugh, H. Wang, C. A. Boyd, R. A. North, and D.
Kabat, “Cell surface receptor for ecotropic host-range mouse
retroviruses: a cationic amino acid transporter,” Archives of
Virology, vol. 9, supplement, pp. 485–494, 1994.
[64] J. L. Blond, D. Lavillette, V. Cheynet et al., “An envelope
glycoprotein of the human endogenous retrovirus HERV-W
is expressed in the human placenta and fuses cells expressing
the type D mammalian retrovirus receptor,” Journal of
Virology, vol. 74, no. 7, pp. 3321–3329, 2000.
[65] Y. Yan, R. C. Knoper, and C. A. Kozak, “Wild mouse variants
of envelope genes of xenotropic/polytropic mouse gam-
maretroviruses and their XPR1 receptors elucidate receptor
determinants of virus entry,” Journal of Virology, vol. 81, no.
19, pp. 10550–10557, 2007.
[66] E. C. Hawkins, “Saliva and tear tests for feline leukemia
virus,”JournaloftheAmericanVeterinaryMedicalAssociation,
vol. 199, no. 10, pp. 1382–1385, 1991.
[67] O. Jarrett, “Overview of feline leukemia virus research,”
Journal of the American Veterinary Medical Association, vol.
199, no. 10, pp. 1279–1281, 1991.
[68] W. D. Hardy Jr., P. W. Hess, and M. Essex, “Horizontal
transmission of feline leukemia virus in cats,” Bibliotheca
Haematologica, vol. no.40, pp. 67–74, 1975.
[69] J. Overbaugh, A. D. Miller, and M. V. Eiden, “Receptors and
entry cofactors for retroviruses include single and multiple
transmembrane-spanningproteinsaswellasnewlydescribed
glycophosphatidylinositol-anchored and secreted proteins,”
Microbiology and Molecular Biology Reviews, vol. 65, no. 3,
pp. 371–389, 2001.16 Advances in Virology
[70] M. C. Adamson, J. Silver, and C. A. Kozak, “The mouse
homolog of the Gibbon ape leukemia virus receptor: genetic
mapping and a possible receptor function in rodents,”
Virology, vol. 183, no. 2, pp. 778–781, 1991.
[71] R. Mendoza, M. M. Anderson, and J. Overbaugh, “A putative
thiamine transport protein is a receptor for feline leukemia
virus subgroup A,” Journal of Virology,v o l .8 0 ,n o .7 ,p p .
3378–3385, 2006.
[72] M. A. Sommerfelt and R. A. Weiss, “Receptor interference
groups of 20 retroviruses plating on human cells,” Virology,
vol. 176, no. 1, pp. 58–69, 1990.
[ 7 3 ] A .C .v a nd e rK u y l ,J .T .D e k k e r ,a n dJ .G o u d s m i t ,“ D i s c o v e ry
of a new endogenous type C retrovirus (FcEV) in cats: evi-
dence for RD-114 being an FcEV(Gag-Pol)/baboon endoge-
nous virus BaEV(Env) recombinant,” Journal of Virology, vol.
73, no. 10, pp. 7994–8002, 1999.
[74] Y. Takeuchi, F. L. C. Cosset, P. J. Lachmann, H. Okada, R. A.
Weiss, and M. K. L. Collins, “Type C retrovirus inactivation
by human complement is determined by both the viral
genome and the producer cell,” Journal of Virology, vol. 68,
no. 12, pp. 8001–8007, 1994.
[75] H. C. T. Groom, M. W. Yap, R. P. Gal˜ a o ,S .J .D .N e i l ,a n d
K. N. Bishop, “Susceptibility of xenotropic murine leukemia
virus-related virus (XMRV) to retroviral restriction factors,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 11, pp. 5166–5171, 2010.
[76] K. Stieler and N. Fischer, “Apobec 3G eﬃciently reduces
infectivity of the human exogenous gammaretrovirus
XMRV,” PLoS ONE, vol. 5, no. 7, Article ID e11738, 2010.
[77] L. Carthagena, M. C. Parise, M. Ringeard, M. K. Chelbi-Alix,
U. Hazan, and S. Nisole, “Implication of TRIMalpha and
TRIMCyp in interferon-induced anti-retroviral restriction
activities,” Retrovirology, vol. 5, article 59, 2008.
[78] B. Song, H. Javanbakht, M. Perron, D. H. Park, M. Stremlau,
and J. Sodroski, “Retrovirus restriction by TRIM5α variants
from Old World and New World primates,” Journal of
Virology, vol. 79, no. 7, pp. 3930–3937, 2005.
[79] M. W. Yap, S. Nisole, C. Lynch, and J. P. Stoye, “Trim5α
protein restricts both HIV-1 and murine leukemia virus,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 101, no. 29, pp. 10786–10791, 2004.
[80] C. M. Okeoma, N. Lovsin, B. M. Peterlin, and S. R.
Ross, “APOBEC3 inhibits mouse mammary tumour virus
replication in vivo,” Nature, vol. 445, no. 7130, pp. 927–930,
2007.
[81] E. Takeda, S. Tsuji-Kawahara, M. Sakamoto et al., “Mouse
APOBEC3 restricts friend leukemia virus infection and
pathogenesis in vivo,” Journal of Virology, vol. 82, no. 22, pp.
10998–11008, 2008.
[82] E. C. Knouf, M. J. Metzger, P. S. Mitchell et al., “Multiple
integrated copies and high-level production of the human
retrovirus XMRV (xenotropic murine leukemia virus-related
virus) from 22Rv1 prostate carcinoma cells,” Journal of
Virology, vol. 83, no. 14, pp. 7353–7356, 2009.
[83] K. Stieler, C. Schulz, M. Lavanya, M. Aepfelbacher, C.
Stocking, and N. Fischer, “Host range and cellular tropism
of the human exogenous gammaretrovirus XMRV,” Virology,
vol. 399, no. 1, pp. 23–30, 2010.
[84] O.Hohn,K.Strohschein,A.U.Brandtetal.,“Noevidencefor
XMRV in German CFS and MS patients with fatigue despite
the ability of the virus to infect human blood cells in vitro,”
PLoS ONE, vol. 5, no. 12, Article ID e15632, 2010.
[85] M. Cornelissen, F. Zorgdrager, P. Blom et al., “Lack of
detection of XMRV in seminal plasma from HIV-1 infected
men in The Netherlands,” PLoS ONE,v o l .5 ,n o .8 ,A r t i c l eI D
e12040, 2010.
[86] E. Barnes, P. Flanagan, A. Brown et al., “Failure to detect
xenotropic murine leukemia virus-related virus in blood of
individuals at high risk of blood-borne viral infections,”
Journal of Infectious Diseases, vol. 202, no. 10, pp. 1482–1485,
2010.
[87] B. P. Danielson, G. E. Ayala, and J. T. Kimata, “Detection
of xenotropic murine leukemia virus-related virus in normal
and tumor tissue of patients from the southern United States
with prostate cancer is dependent on speciﬁc polymerase
chain reaction conditions,” Journal of Infectious Diseases, vol.
202, no. 10, pp. 1470–1477, 2010.
[88] N.Bannert,“Editorial:isanovelhumanretrovirusassociated
with prostate cancer and chronic fatigue syndrome?” Future
Microbiology, vol. 5, no. 5, pp. 689–691, 2010.
[89] O. Erlwein, S. Kaye, M. O. McClure et al., “Failure to detect
the novel retrovirus XMRV in chronic fatigue syndrome,”
PLoS ONE, vol. 5, no. 1, Article ID e8519, 2010.
[90] H.C.T.Groom,V.C.Boucherit,K.Makinsonetal.,“Absence
of xenotropic murine leukaemia virus-related virus in UK
patients with chronic fatigue syndrome,” Retrovirology, vol.
7, article 10, 2010.
[91] T. J. Henrich, J. Z. Li, D. Felsenstein et al., “Xenotropic
murine leukemia virus-related virus prevalence in patients
with chronic fatigue syndrome or chronic immunomodula-
tory conditions,” Journal of Infectious Diseases, vol. 202, no.
10, pp. 1478–1481, 2010.
[92] P. Hong, J. Li, and Y. Li, “Failure to detect Xenotropic
murine leukaemia virus-related virus in Chinese patients
with chronic fatigue syndrome,” Virology Journal, vol. 7,
article 224, 2010.
[93] S. Hue, E. R. Gray, A. Gall et al., “Disease-associated XMRV
sequences are consistent with laboratory contamination,”
Retrovirology, vol. 7, article 111, 2010.
[94] B. Oakes, A. K. Tai, O. Cingoz et al., “Contamination of
human DNA samples with mouse DNA can lead to false
detection of XMRV-like sequences,” Retrovirology, vol. 7,
article 109, 2010.
[95] M. J. Robinson, O. W. Erlwein, S. Kaye et al., “Mouse
DNA contamination in human tissue tested for XMRV,”
Retrovirology, vol. 7, article 108, 2010.
[96] J. Kaiser, “Chronic fatigue syndrome. Studies point to
possible contamination in XMRV ﬁndings,” Science, vol. 331,
no. 6013, p. 17, 2011.
[97] G. W. Verhaegh, A. S. de Jong, F. P. Smit, S. A. Jannink,
W. J.G. Melchers, and J. A. Schalken, “Prevalence of human
xenotropic murine leukemia virus-related gammaretrovirus
(XMRV) in dutch prostate cancer patients,” Prostate, vol. 71,
no. 4, pp. 415–420, 2011.
[98] F. J. van Kuppeveld, A. S. de Jong, K. H. Lanke et al., “Preva-
lence of xenotropic murine leukaemia virus-related virus in
patients with chronic fatigue syndrome in the Netherlands:
retrospective analysisof samplesfroman establishedcohort,”
British Medical Journal, vol. 340, article c1018, 2010.
[99] J. A. Garson, P. Kellam, and G. J. Towers, “Analysis of XMRV
integration sites from human prostate cancer tissues suggests
PCR contamination rather than genuine human infection,”
Retrovirology, vol. 8, article 13, 2011.
[100] R. A. Smith, “Contamination of clinical specimens with
MLV-encoding nucleic acids: implications for XMRV and
other candidate human retroviruses,” Retrovirology, vol. 7,
article 112, 2010.Advances in Virology 17
[101] E. Sato, R. A. Furuta, and T. Miyazawa, “An endogenous
murine leukemia viral genome contaminant in a commercial
RT-PCR Kit is ampliﬁed using standard primers for XMRV,”
Retrovirology, vol. 7, article 110, 2010.
[102] J. A. Mikovits, Y. Huang, M. A. Pfost et al., “Distribution
of xenotropic murine leukemia virus-related virus (XMRV)
infection in chronic fatigue syndrome and prostate cancer,”
AIDS Reviews, vol. 12, no. 3, pp. 149–152, 2010.
[103] J. A. Mikovits, V. C. Lombardi, M. A. Pfost, K. S. Hagen, and
F. W. Ruscetti, “Detection of an infectious retrovirus, XMRV,
in blood cells of patients with chronic fatigue syndrome,”
Virulence, vol. 1, no. 5, pp. 386–390, 2010.
[104] R. S. Arnold, N. V. Makarova, A. O. Osunkoya et al., “XMRV
infection in patients with prostate cancer: novel serologic
assay and correlation with PCR and FISH,” Urology, vol. 75,
no. 4, pp. 755–761, 2010.
[105] W. M. Switzer, H. Jia, O. Hohn et al., “Absence of evidence of
xenotropic murine leukemia virus-related virus infection in
persons with chronic fatigue syndrome and healthy controls
in the United States,” Retrovirology, vol. 7, article 57, 2010.
[106] O.Hohn,H.Krause,P.Barbarottoetal.,“Lackofevidencefor
xenotropic murine leukemia virus-related virus(XMRV) in
Germanprostatecancerpatients,”Retrovirology,vol.6,article
92, 2009.
[107] S. Sabunciyan, N. Mandelberg, C. S. Rabkin, R. Yolken,
and R. Viscidi, “No diﬀerence in antibody titers against
xenotropic MLV related virus in prostate cancer cases and
cancer-free controls,” Molecular and Cellular Probes, vol. 25,
no. 2-3, pp. 134–136, 2011.
[108] R.A.Furuta,T.Miyazawa,T.Sugiyamaetal.,“Noassociation
of xenotropic murine leukemia virus-related virus with
prostate cancer or chronic fatigue syndrome in Japan,”
Retrovirology, vol. 8, article 20, 2011.
[109] X. Qiu, P. Swanson, K. C. Luk et al., “Characterization of
antibodies elicited by XMRV infection and development of
immunoassays useful for epidemiologic studies,” Retrovirol-
ogy, vol. 7, article 68, 2010.
[110] R.Schlaberg,D.J.Choe,K.R.Brown,H.M.Thaker,andI.R.
Singh, “XMRV is present in malignant prostatic epithelium
and is associated with prostate cancer, especially high-grade
tumors,”ProceedingsoftheNationalAcademyofSciencesofthe
United States of America, vol. 106, no. 38, pp. 16351–16356,
2009.
[111] C. Y. Chiu, S. Rouskin, A. Koshy et al., “Microarray detection
of human parainﬂuenzavirus 4 infection associated with
respiratory failure in an immunocompetent adult,” Clinical
Infectious Diseases, vol. 43, no. 8, pp. e71–e76, 2006.
[112] V. R. Placencio, A. R. Sharif-Afshar, X. Li et al., “Stromal
transforming growth factor-β signaling mediates prostatic
response to androgen ablation by paracrine Wnt activity,”
Cancer Research, vol. 68, no. 12, pp. 4709–4718, 2008.
[113] N. A. Bhowmick, E. G. Neilson, and H. L. Moses, “Stromal
ﬁbroblasts in cancer initiation and progression,” Nature, vol.
432, no. 7015, pp. 332–337, 2004.
[114] V. Montel, E. S. Mose, and D. Tarin, “Tumor-stromal
interactions reciprocally modulate gene expression patterns
during carcinogenesis and metastasis,” International Journal
of Cancer, vol. 119, no. 2, pp. 251–263, 2006.
[115] D. Tarin, “Tissue interactions in morphogenesis, morphosta-
sis and carcinogenesis,” Journal of Theoretical Biology, vol. 34,
no. 1, pp. 61–72, 1972.
[116] A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll,
T. D. Tlsty, and G. R. Cunha, “Carcinoma-associated ﬁbrob-
lasts direct tumor progression of initiated human prostatic
epithelium,” Cancer Research, vol. 59, no. 19, pp. 5002–5011,
1999.
[117] S. W. Hayward, Y. Wang, M. Cao et al., “Malignant transfor-
mation in a nontumorigenic human prostatic epithelial cell
line,” Cancer Research, vol. 61, no. 22, pp. 8135–8142, 2001.
[118] L. A. Jason, A. Boulton, N. S. Porter, T. Jessen, M. G. Njoku,
and F. Friedberg, “Classiﬁcation of myalgic encephalomyeli-
tis/chronic fatigue syndrome by types of fatigue,” Behavioral
Medicine, vol. 36, no. 1, pp. 24–31, 2010.
[119] O. Zachrisson, B. Regland, M. Jahreskog, M. Kron, and C. G.
Gottfries, “A rating scale for ﬁbromyalgia and chronic fatigue
syndrome (the FibroFatigue scale),” Journal of Psychosomatic
Research, vol. 52, no. 6, pp. 501–509, 2002.
[120] J. Blomberg, “Swedish study comes up empty,” in Proceedings
of the 1st XMRV Conference, Bethesda, Md, USA, 2010.
[121] L. Zhang, J. Gough, D. Christmas et al., “Microbial infec-
tions in eight genomic subtypes of chronic fatigue syn-
drome/myalgicencephalomyelitis,”JournalofClinicalPathol-
ogy, vol. 63, no. 2, pp. 156–164, 2010.
[122] K. Mørch, K. Hanevik, G. Rortveit et al., “Severity of
Giardia infection associated with post-infectious fatigue
and abdominal symptoms two years after,” BMC Infectious
Diseases, vol. 9, article 206, 2009.
[123] K. Mørch, K. Hanevik, G. Rortveit, K. A. Wensaas, and N.
Langeland, “High rate of fatigue and abdominal symptoms 2
yearsafteranoutbreakofgiardiasis,”TransactionsoftheRoyal
Society of Tropical Medicine and Hygiene, vol. 103, no. 5, pp.
530–532, 2009.
[124] M. B. Gardner, C. A. Kozak, and S. J. O’Brien, “The Lake
Casitas wild mouse: evolving genetic resistance to retroviral
disease,” Trends in Genetics, vol. 7, no. 1, pp. 22–27, 1991.
[125] O. Jarrett, “Pathogenicity of feline leukemia virus is com-
monly associated with variant viruses,” Leukemia, vol. 6,
supplement 3, pp. 153S–154S, 1992.
[126] R. R. Watson, “Resistance to intestinal parasites during
murine AIDS: role of alcohol and nutrition in immune
dysfunction,” Parasitology, vol. 107, supplement, pp. S69–
S74, 1993.
[127] P. Jolicoeur, “Murine acquired immunodeﬁciency syndrome
(MAIDS): an animal model to study the AIDS pathogenesis,”
FASEB Journal, vol. 5, no. 10, pp. 2398–2405, 1991.
[128] C. S. Via, H. C. Morse III, and G. M. Shearer, “Altered
immunoregulation and autoimmune aspects of HIV infec-
tion: relevant murine models,” Immunology Today, vol. 11,
no. 7, pp. 250–255, 1990.
[129] R. R. Watson, “A murine retroviurs model for studies of the
role of cofactors and ethanol in AIDS development,” NIDA
Research Monograph Series, no. 96, pp. 166–180, 1990.
[130] R. R. Watson, “Murine models for acquired immune deﬁ-
ciency syndrome,” Life Sciences, vol. 44, no. 3, pp. 3–15, 1989.
[131] E. A. Hoover, S. L. Quackenbush, M. L. Poss et al.,
“Pathogenic mechanisms of immunodeﬁciency syndrome
and aplastic anemia induced by feline leukemia viruses,”
Developments in Biological Standardization, vol. 72, pp. 163–
166, 1990.
[132] J. Overbaugh, P. R. Donahue, S. L. Quackenbush, E. A.
Hoover, and J. I. Mullins, “Molecular cloning of a feline
leukemia virus that induces fatal immunodeﬁciency disease
in cats,” Science, vol. 239, no. 4842, pp. 906–910, 1988.
[133] N. Tabata, M. Miyazawa, R. Fujisawa, Y. A. Takei, H. Abe,
and K. Hashimoto, “Establishment of monoclonal anti-
retroviralgp70autoantibodiesfromMRL/lprlupusmiceand18 Advances in Virology
induction of glomerular gp70 deposition and pathology by
transferintonon-autoimmunemice,”JournalofVirology,vol.
74, no. 9, pp. 4116–4126, 2000.
[134] S. K. Datta, P. J. McConahey, N. Manny, A. N. Theoﬁlopou-
los, F. J. Dixon, and R. S. Schwartz, “Genetic studies of
autoimmunity and retrovirus expression in crosses of New
Zealand Black mice. II. The viral envelope glycoprotein
gp70,” Journal of Experimental Medicine, vol. 147, no. 3, pp.
872–881, 1978.
[135] R.Schlaberg,D.J.Choe,K.R.Brown,H.M.Thaker,andI.R.
Singh, “XMRV is present in malignant prostatic epithelium
and is associated with prostate cancer, especially high-grade
tumors,”ProceedingsoftheNationalAcademyofSciencesofthe
United States of America, vol. 106, no. 38, pp. 16351–16356,
2009.
[136] Y. Takeuchi, M. O. McClure, and M. Pizzato, “Identiﬁcation
of gammaretroviruses constitutively released from cell lines
used for human immunodeﬁciency virus research,” Journal
of Virology, vol. 82, no. 24, pp. 12585–12588, 2008.
[137] M. Dewannieux, D. Ribet, and T. Heidmann, “Risks linked
to endogenous retroviruses for vaccine production: a general
overview,” Biologicals, vol. 38, no. 3, pp. 366–370, 2010.
[138] R. A. Weiss, “A cautionary tale of virus and disease,” BMC
Biology, vol. 8, article 124, 2010.
[139] C. Voisset, R. A. Weiss, and D. J. Griﬃths, “Human RNA
“rumor” viruses: the search for novel human retroviruses in
chronicdisease,”MicrobiologyandMolecularBiologyReviews,
vol. 72, no. 1, pp. 157–196, 2008.
[140] A. Forsman, D. Uzameckis, L. R¨ onnblom et al., “Single-tube
nested quantitative PCR: a rational and sensitive technique
for detection of retroviral DNA. Application to RERV-
H/HRV-5 and conﬁrmation of its rabbit origin,” Journal of
Virological Methods, vol. 111, no. 1, pp. 1–11, 2003.
[141] J. W. Hartley, L. H. Evans, K. Y. Green et al., “Expression
of infectious murine leukemia viruses by RAW264.7 cells, a
potential complication for studies with a widely used mouse
macrophage cell line,” Retrovirology, vol. 5, article 1, 2008.
[142] A. Stang, E. Petrasch-Parwez, S. Brandt et al., “Unintended
spread of a biosafety level 2 recombinant retrovirus,” Retro-
virology, vol. 6, article 86, 2009.
[143] R. Yoshikawa, E. Sato, and T. Miyazawa, “Contamination of
infectious RD-114 virus in vaccines produced using non-
feline cell lines,” Biologicals, vol. 39, no. 1, pp. 33–37, 2011.
[144] T. F. Malivanova and S. V. Litvinov, “Antibodies to retro-
viruses of types C and D in female patients with benign and
malignant mammary tumours,” Acta Virologica, vol. 34, no.
1, pp. 19–26, 1990.
[145] R. H. Reeves and S. J. O’Brien, “Molecular genetic charac-
terization of the RD-114 gene family of endogenous feline
retroviral sequences,” Journal of Virology,v o l .5 2 ,n o .1 ,p p .
164–171, 1984.
[146] P. Herbrink, J. E. T. Moen, J. Brouwer, and S. O. Warnaar,
“Detection of antibodies cross-reactive with type C RNA
tumor viral p30 protein in human sera and exudate ﬂuids,”
Cancer Research, vol. 40, no. 1, pp. 166–173, 1980.
[147] K. Welte, U. Ebener, and P. Chandra, “Serological character-
ization of a puriﬁed reverse transcriptase from osteosarcoma
of a child,” Cancer Letters, vol. 7, no. 4, pp. 189–195, 1979.
[148] P. Chandra, S. Balikcioglu, and B. Mildner, “Biochemical and
immunological characterization of a reverse transcriptase
from human melanoma tissue,” Cancer Letters, vol. 5, no. 6,
pp. 299–310, 1978.
[149] H. S. Kaplan, R. S. Goodenow, A. L. Epstein, S. Gartner, A.
Decleve, and P. N. Rosenthal, “Isolation of a type C RNA
virus from an established human histiocytic lymphoma cell
line,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 74, no. 6, pp. 2564–2568, 1977.
[150] M. Strand and J. T. August, “Type C RNA virus gene
expression in human tissue,” Journal of Virology, vol. 14, no.
6, pp. 1584–1596, 1974.
[151] R. M. McAllister, M. Nicolson, and M. B. Gardner, “RD
114 virus compared with feline and murine type C viruses
released from RD cells,” Nature, vol. 242, no. 116, pp. 75–78,
1973.
[152] K.V.Ilyin,J.G.Kzhyshkowska,L.R.Imamovaetal.,“TypeD
retrovirus speciﬁc sequences in lymphocytes of the children
withBurkitt-typelymphomaandtheirparents,”Immunology
Letters, vol. 78, no. 1, pp. 51–54, 2001.
[153] W. Hofmann, B. Reichart, A. Ewald et al., “Cofactor
requirements for nuclear export of Rev response element
(RRE)-andconstitutivetransportelement(CTE)-containing
retroviral RNAs: an unexpected role for actin,” Journal of Cell
Biology, vol. 152, no. 5, pp. 895–910, 2001.
[154] J. G. Kzhyshkowska, A. V. Kiselev, G. A. Gordina et al.,
“Markers of type D retroviruses in children with Burkitt’s-
type lymphoma,” Immunology Letters, vol. 53, no. 2-3, pp.
101–104, 1996.
[155] R. J. Ford, L. A. Donehower, and R. C. Bohannon, “Studies
on a type D retrovirus isolated from an AIDS patient
lymphoma,” AIDS Research and Human Retroviruses, vol. 8,
no. 5, pp. 742–751, 1992.
[156] R. C. Bohannon, L. A. Donehower, and R. J. Ford, “Isolation
of a type D retrovirus from B-cell lymphomas of a patient
with AIDS,” Journal of Virology, vol. 65, no. 11, pp. 5663–
5672, 1991.
[157] L. A. Donehower, R. C. Bohannon, R. J. Ford, and R. A.
Gibbs,“Theuseofprimersfromhighlyconservedpolregions
to identify uncharacterized retorviruses by the polymerase
chain reaction,” Journal of Virological Methods, vol. 28, no.
1, pp. 33–46, 1990.
[158] H. Krause, W. Uckert, and V. Wunderlich, “Use of molecular
cloned viral genomes for studies into interrelationship
between type D retroviruses from monkey and human cells,”
Archiv fur Experimentelle Veterinarmedizin, vol. 44, no. 6, pp.
931–933, 1990.
[159] H. Krause, V. Wunderlich, and W. Uckert, “Molecular
cloning of a type D retrovirus from human cells (PMFV) and
its homology to simian acquired immunodeﬁciency type D
retroviruses,” Virology, vol. 173, no. 1, pp. 214–222, 1989.
[160] D. F. J. Purcell, N. J. Deacon, and I. F. C. McKenzie, “The
human non-lineage antigen CD46 (HuLy-m5) and primate
retroviral gp70 molecules share protein-deﬁned antigenic
determinants,” Immunology and Cell Biology, vol. 67, no. 5,
pp. 279–289, 1989.
[161] M. Popovic, V. S. Kalyanaraman, M. S. Reitz, and M. G.
Sarngadharan, “Identiﬁcation of the RPMI 8226 retrovirus
and its dissemination as a signiﬁcant contaminant of some
widely used human and marmoset cell lines,” International
Journal of Cancer, vol. 30, no. 1, pp. 93–99, 1982.
[162] M.Fukuda,H.J.Wanebo,andL.Tsuei,“Leukocytemigration
inhibition among breast cancer patients in response to
various oncogenic viruses,” Journal of the National Cancer
Institute, vol. 64, no. 3, pp. 431–437, 1980.
[163] W. Uckert, V. Wunderlich, and E. Bender, “The protein
pattern of PMF virus, a type-D retrovirus from malignantAdvances in Virology 19
permanent humancell lines,”Archives of Virology, vol. 64,no.
2, pp. 155–166, 1980.
[164] L. Thiry, S. Sprecher-Goldberger, M. Bossens, and F. Neuray,
“Cell mediated immune response to simian oncornavirus
antigens in pregnant women,” Journal of the National Cancer
Institute, vol. 60, no. 3, pp. 527–532, 1978.
[165] S. G. Devare, L. O. Arthur, D. L. Fine, and J. R. Stephen-
son, “Primate retroviruses: immunological cross-reactivity
between major structural proteins of new and old world
primate virus isolates,” Journal of Virology,v o l .2 5 ,n o .3 ,p p .
797–805, 1978.
[166] A. Malmsten, D. H. L. Ekstrand, L. ˚ Akerblom et al., “A col-
orimetric reverse transcriptase assay optimized for Moloney
murine leukemia virus, and its use for characterization
of reverse transcriptases of unknown identity,” Journal of
Virological Methods, vol. 75, no. 1, pp. 9–20, 1998.
[167] J. F. Sears, R. Repaske, and A. S. Khan, “Improved Mg2+-
based reverse transcriptase assay for detection of primate
retroviruses,” Journal of Clinical Microbiology,v o l .3 7 ,n o .6 ,
pp. 1704–1708, 1999.
[168] H. Pyra, J. Boni, and J. Schupbach, “Ultrasensitive retrovirus
detection by a reverse transcriptase assay based on product
enhancement,” Proceedings of the National Academy of Sci-
ences of the United States of America, vol. 91, no. 4, pp. 1544–
1548, 1994.
[169] N. Fischer, C. Schulz, K. Stieler et al., “Xenotropic murine
leukemia virus-related gammaretro virus in respiratory
tract,” Emerging Infectious Diseases, vol. 16, no. 6, pp. 1000–
1002, 2010.
[170] K. Lee, F. W. Ruscetti, P. Lloyd, A. Rein, G. Fanning-
Heidecker, and V. N. Kewalramani, “Development of a GFP-
indicator cell line for the detection of XMRV,” in Proceedings
of the 1st XMRV conference, National Institutes of Health,
Bethesda, Md, USA, 2010.
[171] M. Deichmann, J. B. Huder, C. Kleist, H. N¨ aher, J.
Sch¨ upbach, and J. B¨ oni, “Detection of reverse transcriptase
activity in human melanoma cell lines and identiﬁcation of
a murine leukemia virus contaminant,” Archives of Dermato-
logical Research, vol. 296, no. 8, pp. 345–352, 2005.
[172] R. Yoshikawa, E. Sato, T. Igarashi, and T. Miyazawa, “Charac-
terizationofRD-114virusisolatedfromacommercialcanine
vaccine manufactured using CRFK cells,” Journal of Clinical
Microbiology, vol. 48, no. 9, pp. 3366–3369, 2010.
[173] T. Miyazawa, “Endogenous retroviruses as potential hazards
for vaccines,” Biologicals, vol. 38, no. 3, pp. 371–376, 2010.
[174] T.Miyazawa,R.Yoshikawa,M.Golder,M.Okada,H.Stewart,
and M. Palmarini, “Isolation of an infectious endogenous
retrovirus in a proportion of live attenuated vaccines for
pets,” Journal of Virology, vol. 84, no. 7, pp. 3690–3694, 2010.
[175] M. Zhang, S. Lute, L. Norling et al., “A novel, Q-PCR based
approach to measuring endogenous retroviral clearance
by capture protein a chromatography,” Biotechnology and
Bioengineering, vol. 102, no. 5, pp. 1438–1447, 2009.
[176] A. Chang and S. Dusing, “Practical assay issues with the
PERT/PBRT assay: a highly sensitive reverse transcriptase
assay,” Developments in Biologicals, vol. 123, pp. 91–97, 2006.
[177] J. Blomberg, G. Folsch, I. Nilsson, and R. Faldt,
“Immunoglobulin G antibodies binding to a synthetic
peptide deduced from the nucleotide sequence of the env
gene of HTLV I in patients with leukemia and rheumatoid
arthritis, HLA sensitized persons and blood donors,”
Leukemia Research, vol. 9, no. 9, pp. 1111–1116, 1985.
[178] J. Blomberg, A. Lawoko, R. Pipkorn et al., “A survey of syn-
thetic HIV-1 peptides with natural and chimeric sequences
for diﬀerential reactivity with Zimbabwean, Tanzanian and
Swedish HlV-1-positive sera,” AIDS, vol. 7, no. 6, pp. 759–
767, 1993.
[179] J. Blomberg, T. Moestrup, J. Frimand et al., “HTLV-I and -
II in intravenous drug users from Sweden and Denmark,”
Scandinavian Journal of Infectious Diseases,v o l .2 6 ,n o .1 ,p p .
23–26, 1994.
[180] J. Blomberg, M. Robert-Guroﬀ,W .A .B l a t t n e r ,a n dR .
Pipkorn, “Type- and group-speciﬁc continuous antigenic
determinants of HTLV. Use of synthetic peptides for serotyp-
ing of HTLV-I and -II infection,” Journal of Acquired Immune
Deﬁciency Syndromes, vol. 5, no. 3, pp. 294–302, 1992.
[181] J. Blomberg, E. Vincic, C. Jonsson, P. Medstrand, and R. Pip-
korn, “Identiﬁcation of regions of HIV-1 p24 reactive with
sera which give “indeterminate” results in electrophoretic
immunoblots with the help of long synthetic peptides,” AIDS
Research and Human Retroviruses, vol. 6, no. 12, pp. 1363–
1372, 1990.
[182] P. J. Klasse, R. Pipkorn, and J. Blomberg, “Presence of
antibodies to a putatively immunosuppressive part of human
immunodeﬁciency virus (HIV) envelope glycoprotein gp41
is strongly associated with health among HIV-positive sub-
jects,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.85,no.14,pp.5225–5229,1988.
[183] N. Onlamoon, J. D. Gupta, P. Sharma et al., “Infection, viral
dissemination, and antibody responses of rhesus macaques
exposed to the human gammaretrovirus XMRV,” Journal of
Virology, vol. 85, no. 9, pp. 4547–4557, 2011.
[184] T. Sakuma, J. M. Tonne, K. A. Squillace et al., “Early events in
retrovirus XMRV infection of the wild-derived mouse Mus
pahari,” Journal of Virology, vol. 85, no. 3, pp. 1205–1213,
2011.
[185] W. K. Gillette, D. Esposito, T. E. Taylor, R. F. Hopkins, R. K.
Bagni, and J. L. Hartley, “Purify First: rapid expression and
puriﬁcation of proteins from XMRV,” Protein Expression and
Puriﬁcation, vol. 76, no. 2, pp. 238–247, 2011.
[186] E. P. Lillehoj, G. M. Ford, S. Bachmann, J. Schr¨ oder, E. F.
Torrey, and R. H. Yolken, “Serum antibodies reactive with
non-human primate retroviruses identiﬁed in acute onset
schizophrenia,” Journal of NeuroVirology,v o l .6 ,n o .6 ,p p .
492–497, 2000.
[187] D. K. Langat, E. O. Wango, G. O. Owiti, E. O. Omollo,
and J. M. Mwenda, “Characterisation of retroviral-related
antigens expressed in normal baboon placental tissues,”
African Journal of Health Sciences, vol. 5, pp. 144–152, 1998.
[188] B. Szabo, F. D. Toth, J. Kiss, A. Kiss, and K. Rak, “Antiretro-
viral immune response and plasma interferon in diﬀerent
phasesofchronicgranulocyticleukemia,”LeukemiaResearch,
vol. 17, no. 4, pp. 311–323, 1993.
[189] C. Leib-Mosch, M. Bachmann, R. Brack-Werner, T. Werner,
V. Erﬂe, and R. Hehlmann, “Expression and biological
signiﬁcance of human endogenous retroviral sequences,”
Leukemia, vol. 6, supplement 3, pp. 72S–75S, 1992.
[190] J. Kiss, F. D. Toth, B. Szabo, A. Kiss, and K. Rak, “Retrovirus-
neutralizing antibodies in AML and AMMoL patients: stage-
speciﬁc distribution,” Neoplasma, vol. 36, no. 2, pp. 191–197,
1989.
[191] F. D. T´ oth, L. V´ aczi, B. Szab´ o et al., “Detection of main
core proteins of simian C-type viruses and human retrovirus
HTLV and antibodies to them in patients with lymphoid
malignancies,” Acta Microbiologica Hungarica, vol. 32, no. 3,
pp. 267–273, 1985.
[192] S. Maeda, K. Yonezawa, and A. Yachi, “Serum antibody
reactingwithplacentalsyncytiotrophoblastinseraofpatients20 Advances in Virology
with autoimmune diseases—a possible relation to type C
RNA retrovirus,” Clinical and Experimental Immunology, vol.
60, no. 3, pp. 645–653, 1985.
[193] F. D. Toth, L. Vaczi, B. Szabo et al., “Studies on the speciﬁcity
of human antibodies reacting with GP70 and P15 antigens
of baboon endogenous (BaEV) and gibbon ape leukaemia
(GaLV) viruses,” Acta Virologica, vol. 28, no. 3, pp. 191–197,
1984.
[194] B. Szab´ o, F. D. T´ oth, L. V´ a c z i ,A .R ´ ethy, A. Kiss, and K.
R´ ak, “Cellular and humoral cytotoxicity in patients with
leukaemia and preleukaemia. II. Oncovirus speciﬁcity of the
reaction,” Acta Microbiologica Hungarica,v o l .3 1 ,n o .4 ,p p .
365–372, 1984.
[195] N. Anh-Tuan, F. D. Toth, B. Szabo et al., “Antibodies to
primateretrovirusantigensincirculatingimmunecomplexes
of patients with acute myeloid leukemia,” Leukemia Research,
vol. 8, no. 5, pp. 863–871, 1984.
[196] S. Maeda, R. C. Mellors, and J. W. Mellors, “Immunohisto-
logicdetectionofantigenrelatedtoprimatetypeCretrovirus
p30 in normal human placentas,” American Journal of
Pathology, vol. 112, no. 3, pp. 347–356, 1983.
[197] R. Hehlmann, H. Schetters, V. Erﬂe, and C. Leib-Mosch,
“Detection and biochemical characterization of antigens in
human leukemic sera that cross-react with primate C-type
viral proteins (M(r) 30,000),” Cancer Research, vol. 43, no. 1,
pp. 392–399, 1983.
[198] D. Wernicke and R. Kurth, “Human antibodies recognizing
the envelope glycoprotein of the baboon endogenous virus
BaEV are of heterophil origin,” Medical Microbiology and
Immunology, vol. 170, no. 2, pp. 135–143, 1981.
[199] F. D. Toth, L. Vaczi, and J. Kiss, “Detection by radioim-
munoassay of antigens related to the P30 polypeptides
of primate type C oncoviruses in peripheral leukocytes
from patients with chronic myelogenous leukaemia,” Acta
Virologica, vol. 25, no. 6, pp. 376–380, 1981.
[200] L. E. Posner, M. Robert-Guroﬀ, and V. S. Kalyanaraan,
“Natural antibodies to the human T cell lymphoma virus
in patients with cutaneous T cell lymphomas,” Journal of
Experimental Medicine, vol. 154, no. 2, pp. 333–346, 1981.
[201] S. A. Stass, T. M. Phillips, O. S. Weislow, E. Perlin, and
H. R. Schumacher, “Antigen-antibody complexes related
to the baboon endogenous virus in humans with acute
lymphoblastic leukemia-hand mirror variant (ALL-HMC),”
Blood, vol. 56, no. 4, pp. 661–666, 1980.
[202] F. Wong-Staal, S. Josephs, R. D. Favera, and R. Gallo,
“Detection of integrated type-C viral DNA fragments in two
primates (human and gibbon) by the restriction enzyme
blottingtechnique,”HamatologieundBluttransfusion,vol.23,
pp. 553–560, 1979.
[203] J. Blomberg, O. Nived, R. Pipkorn, A. Bengtsson, D. Erlinge,
and G. Sturfelt, “Increased antiretroviral antibody reactivity
in sera from a deﬁned population of patients with systemic
lupus erythematosus: correlation with autoantibodies and
clinical manifestations,” Arthritis and Rheumatism, vol. 37,
no. 1, pp. 57–66, 1994.
[204] B. C. Satterﬁeld, R. A. Garcia, H. Jia, S. Tang, H. Zheng,
and W. M. Switzer, “Serologic and PCR testing of persons
with chronic fatigue syndrome in the United States shows no
association with xenotropic or polytropic murine leukemia
virus-related viruses,” Retrovirology, vol. 8, article 12, 2011.
[205] M. J. Metzger and A. D. Miller, “Acutely transforming retro-
virus expressing Nras generated from HT-1080 ﬁbrosarcoma
cells infected with the human retrovirus XMRV,” Journal of
Virology, vol. 84, no. 15, pp. 7908–7910, 2010.
[206] A. Lawoko, B. Johansson, D. Rabinayaran, R. Pipkorn, and
J. Blomberg, “Increased immunoglobulin G, but not M,
binding to endogenous retroviral antigens in HIV-1 infected
persons,” Journal of Medical Virology, vol. 62, no. 4, pp. 435–
444, 2000.
[207] W. J. Martin, “Possible widespread low-level occurrence of
murine leukemia virus-related gene sequences in humans,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 43, p. E162, 2010.
[208] A. Krook and J. Blomberg, “HTLV-II among injecting
drug users in Stockholm,” Scandinavian Journal of Infectious
Diseases, vol. 26, no. 2, pp. 129–132, 1994.
[209] A. Krook, J. Albert, S. Andersson et al., “Prevalence and risk
factors for HTLV-II infection in 913 injecting drug users
in Stockholm, 1994,” Journal of Acquired Immune Deﬁciency
Syndromes and Human Retrovirology, vol. 15, no. 5, pp. 381–
386, 1997.
[210] M. Zanchetta, A. Anselmi, D. Vendrame et al., “Early therapy
in HIV-1-infected children: eﬀect on HIV-1 dynamics and
HIV-1-speciﬁc immune response,” Antiviral Therapy, vol. 13,
no. 1, pp. 47–55, 2008.
[211] C. Pastori, C. Barassi, F. Lillo et al., “The eﬀe c to fH A A R T
on humoral immune response in primary HIV-1 infected
patients,” Journal of Biological Regulators and Homeostatic
Agents, vol. 16, no. 1, pp. 9–17, 2002.
[212] H. G. Klein, R. Y. Dodd, F. B. Hollinger et al., “Xenotropic
murine leukemia virus-related virus (XMRV) and blood
transfusion: report of the AABB interorganizational XMRV
task force,” Transfusion, vol. 51, no. 3, pp. 654–661, 2011.
[213] R. A. Smith, G. S. Gottlieb, and A. D. Miller, “Susceptibility
of the human retrovirus XMRV to antiretroviral inhibitors,”
Retrovirology, vol. 7, article 70, 2010.